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 The siddha system is one of the ancient type of traditional medicine formulated 
by Siddhars, the blessed people.  
 Siddhar gains its importance by treating the cause of the disease and not merely 
the symptoms. 
 “ேநாநா ேநா«த நா அ¢ தணt  
  வாநா வா~பv ெசய” 
 Siddha is a tamil word that is derived from its root “Sidh” which means 
“perfection in life” or “heavenly bliss” . 
  Siddha system of medicine puts emphasis of three dhosas alteration in these 
three dhosas will cause diseases. 
 According to siddha concept, disease is caused when the normal equilibrium of 
3 humors (Vaatha, Pitham and Kabam) is distributed. The factors which affects this 
equilibrium are environment, climatic conditions, diet and physical activities “ 
Kuzhanthai Maruthuvam” is one among the glorious branches of siddha system inside 
which is hidden an enormous treasure for a healthy society.  
Aamakanam is one among the common disease in pediatrics age group the 
author has taken disease AAMAKANAM as dissertation topic and discussed the topic 
on the basis of siddha aspect as well as modern aspect and about treatment. 
SWASAKUDORI CHOORANAM is chosen for this study reference from 
Agasthiyar vaithiya kaviyam-1500. This medicine has been told to be effective and 
safe for pediatric usage. 
“உறவ} தƫ~பா} ம¯|¢ைழv ெசவாென} 






AIM AND OBJECTIVES 
 
AIM: 
 Aama kanam is one of the commonest illnesses in children. Aama kanam is 
similar to WALRI (Wheeze associated lower Respiratory tract Infection) so 
worked on Aama kanam to get the patient and economical treatment without any side 
effect. The principle aim of the present study is to evaluate the efficacy of the trail 
drugSWASAKUDORI CHOORANAM in the treatment of Aama kanam.  
 
OBJECTIVES  
 The objective of dissertation works is followed by,  
 To identify the Aama kanam and its characters of diseases with the help of 
various book evidence.  
 To explore the etiology, clinical features, diagnosis and investigation of Aama 
kanam through the various Siddha literatures.  
 To correlates the symptoms of Aama kanam with modern aspect. 
 To have the clinical trial in Aama kanam with the trail medicine Swasakudori 
Chooranam. 
 To evaluate the Bio – chemical,Pharmacological and Antimicrobial analysis of 
the drug. 
 To make use of Siddha and modern parameter in the investigation to conform 
the diagnosis and prognosis of the patient. 
 To educate the patients and their parents in terms of prevention of diseases, diet 
and habit. 
  
REVIEW OF SIDDHA LITERATURE 
கண 
இய  
 கண எ}ப¢ கƫ~பv . மா|த{தி} ெதாடƫ ேநாேய 
கணமா. இ¢ ழவt மா|த ேநா ஏபy «¸வ¢ 
ணமாகாம உடலி இ¯|ேத «றி வ¯. ழ|ைதக பா´ 
{¢ ேசா² உz  ப¯வ{தி உzடா ேநாயா.  
 
கைண 
T.V.சாபசிவபைள அகராதி எ}ற ¥லி கண எ}பதைன, 
ஒ¯ ேநா, ைறº, yட, திரyசி என ெபா¯ றி­ளனƫ. 
 இேத ேபா}² கைண எ}ப¢ அ© என ெபா¯பகிற¢. அ© 
(கைண) பய}ப{தி மாƫபன ெச´{¢வ¢ ேபால கைண 
ேநாய´ கப{தி} இ¯~படமான மாƫேப «த}ைமயாக~ 
பாதிtகபகிற¢.  
 
ேநா ேதா}² வய¢  
இ¢ ழ|ைதகள¢ ¬}றா ஆz «த ஏழா ஆz 
வைர ¢}ப{ைதt ெகாt ேநாயா.  
 “எ}னேவ கண¬}² வ¯ட| ெதாyேட  
  ஏழாz மyt மி¯tu கால” 
ேம´ பரராச ேசகர பாலேராக நிதான படல{தி  
 
 “ எ}றேதாƫ கைண கடா«மி~ப எ¸|¢ ெபாuகி  
   நி}றேபƫ பதிெனy தானைற|தி¯ மாz} ேமலாt 
   க}றிய பாலƫ ெமய பzணரzடாz கா² 
   நி}றி ெம}² «}னாணக{தின} «னவன}ேற” 
         -பாட 27௦ 
எ}பத} ¬ல கண ழ|ைதகள} 12 வய¢ வைரய´ 
கா  ேநா எ}² இய©கிற¢. 
 எனேவ கணமான¢ ¬}றாz «த ஏழாz வைர வ¯ 
ேநா என ற~பyள ேபா¢ ேமேல ற~பyட வளtகuகள 
இ¯|¢ கண ழ|ைத பற|த¢ «த12ஆz மy´ 
ேதா}² ேநா எனº ெகாளலா.   
ேநா வ¯ வழி 
           “ஐய¢  ெற}றா அƬைவயƫ ¢யர| த}னா 
           ெசயப ©னல¯|திv ெசறிசல ேதாட த}னா 
           ைபயர வ லா¶ பசி­ட ன¯|த தா´ 
           ¢யேதாƫ ழவ கyt கணuக¶| ேதா}²ம}ேற” 
இதைன, 
      உள ெதளº² இ¯t தாயன¢ உடநிைல 
பாதிtக~பகிற¢. அதனா அ{தாைய அzவா¸ ழ|ைதயன¢ 
உட´ பாதிtக~பy அவதி­²கிற¢. அதிகமான  ஏப 
ேபா¢ சிேல{¢ம அதிகமாக ேசƫவதா´, தாt அதிகமான 
¢யர வ|¢ அைடவதா´, பல நƫகைள~ ப¯வதா´, 
அதிகமான சலேதாட ஏபவதா´, பசி­டன¯t தாய} 
பாைல உzபதா´ ழ|ைதக¶tt கணேநா ஏபகிற¢ என 
“அேயா{திதாசƫ பாலவாகட” ²கிற¢. 
 
கண{தி} வைகக  
1. அேயா{திதாசƫ பாலவாகட 24 வைகயாகº,  
2. ஆவ அளt அ«த «ைறv ¯tக 23 வைக ம² 18 
வைகயாகº, 
3. ஆ{ம ரyசாமிƫதெம§ ைவ{திய சார சuகிரக 25 
வைகயாகº,  
4. பரராசேசகர எ§ ¥லி 18 வைகயாகº, 
5. மதைல ேநா ெதாதி 2 பாக{தி 16 வைகயாகº, 
6. ப«ன பாலவாகட{தி 18 வைகயாகº, 
7. T.V.சாபசிவபைள அகராதி பாக II  26 வைகயாகº, 
8. ஜவரyசாமிƫத எ§ ¥லி வைகயாகº, 
கண{ைத வைகப{தி­ளனƫ. 
 
1.அேயா{திதாசƫ பாலவாகட கண{தி} 24 வைகக ப}வ¯மா²: 
 
1. வளகண  2. மா|தகண 
3. ப{தகண 4. நƫtகண  
5. கபகண 6. பரளகண  
7. லிகண 8. ம|தாரகண 
9. ழிகண  10. எƬகண  
11. மகாகண  12. நராமகண 
13. ஊ¢கண  14. இர{தகண  
15. வரகண 16. «tகண  
17. ெகாதி~©கண  18. ¬லகண  
19. வ tககண  20. ேபராமகண  
21. பறtகண  22. ஆமகண 
23. அ|தககண  24. சிuகிமா|தகண
  
 
2.ஆவஅளt அ«த «ைறv ¯tக ¥லி றி­ள 23 
கண{தி} வைகக ப}வ¯மா²:  
 “ பார~பா கண வ~© பதிெனyடா 
  பானாƫ வாத கண ப{த கண« 
       ேநர~பா ேச{ம கண நƫt கணமா  
       பரள கண ைலt கண|தா} 
 சார~ப ஊ¢ கண ழி கண|தா}  
 ர~பா ெகாதி~© கண பற கண|தா}  
 றி~பான ஆம கண வ tக கண|தாேன” 
“ தானான ேதைர கண «t கண|தா} 
 தனயான ¬லகண ேபாƫ கண|தா}  
 ஊனான ர{த கண வடா மா|த கண|தா§ 
 ஊ¢ மா|தt கணமா மா|த கண|தா§ 
 ேகானான ம|தார கண«| தா§  
 ரான எƬகணமா மி¯ப{¢ ¬}²  
 பானான கணuக ப}னரz மy  
 பாலகƫt ேந¯ெம}² பகƫ|ததாேம “    
 
1. வாதகண  13. வ tககண  
2. ப{த கண  14. பறகண 
3. சிேல{மகண  15. ஆமகண 
4. மா|தகண  16. வறyசிகண  
5. நƫtகண  17. ¬லகண  
6. பரளகண  18. ேபாƫகண  
7. ைலககண 19. இர{தகண 
8. ஊ¢கண  20. நvமா|தகண  
9. ழிகண  21. ஊ¢மா|தகண  
10. ெகாதி~©கண  22. ம|தாரகண   
11. ேதைரகண 23. எƬகண  
12. «tகண    
 
இvெச­ள கணuக பதிெனy எ}² «த பாடலி´ 
ப} இ¯ப{¢ ¬}² எ}² ற~பy அதி ப}னெரz மy 
பாலகƫt வ¯ எ}² ற~பyள¢.   
3.ஆ{ம ரyசாமிƫதெம§ ைவ{திய சார சuகிரக ¥லி றி­ள 
25 வைகக ப}வ¯மா²: 
1. வாதகண  14. பறகண 
2. ப{த கண  15. வ tககண 
3. ேச{மகண  16. ஆமகண 
4. மா|தகண  17. ¬லகண 
5. நƫtகண  18. ேபாƫtகண 
6. ைலகண 19. இர{தtகண 
7. பரளtகண 20. வஷமா|தகண 
8. ஊ¢கண  21. ஊ¢மா|தகண 
9. ழிகண 22. அ|தககண 
10. மாகண  23. வறyசிகண 
11. வரyகண   24. நvமா|தகண 
12. ெகாதி~©கண 25. ம|தாரகண   
13. எƬகண   
 
4.பரராசேசகர எ§ ¥லி பாலேராக நிதான{தி}ப18 வைகயாக 
பƬ{¢ளனƫ அைவ 
“உரெம§u கைணகz «}னேனா¯ைர{தவா²ைர~பtேகzமி}  
 ரெம§ கைண­ெமா}² £uமt கைண­ெமா}²    
 நிரவய ¬ல மிர{த நuக¯ வரyசி ெவ~©t  
 க¯º² மனல} வ uகி யேதாƫ மxச ணல} 
 நலமாu கைணயேனா நி}றி¯ ெவ¶~© மா  
 சாலேவ ச{தி ேம´| த~பலா மா|த ேமக  
 ேமலிதா வைனக ேபால மி|தி கழிvச காச  
 ஆழமாƬ¯ வ~© மாவைய பதிெனyடாேம”       
1. வாதகைண   10. வ uகைண 
2. ப{தகைண 11. ெவ¶~©கைண 
3. ரtகைண 12. ச{திகைண 
4. அ{திரகைண   13. இர{தகைண 





7. மேக|திரகைண 16. மxசyகைண 
8. £tகைண    17. நலtகைண 
9. அனகைண    18. ெவ~©கைண 
 
5.மதைல ேநா ெதாதி இரzடா பாக{தி 23 வைக ²கிற¢. 
இதி 16 மy ழ|ைதt வ¯ என ற~பyள¢ 
 “ பாƫ கண மேரyடா பானாƫ வாத ப{த 
   ேநƫ கப கணº த¯ ஆைமகண வறyைச 
   றேவ ெகாதி~ப கண ² பால உணtக தாேன  
   தாென}ற ேதைர«t த¯ ¬லேபƫ கண|தா} 
   உzண வஷகணº ெர{த ஊ¢ ம|தார மா|த  
   ேகா ² ேகாதார| தா§ ணமி¯~பதி ¬}² 
   பா} பதினா² மy பாலகா சட{திலாேம”    
1. வாதகண  11. ¬லகண 
 
2. ப{த கண  12. ேபாƫகண 
3. கபகண  13. இர{தகண  
4. மா|தகண  14. ஊ¢மா|தகண 
5. நƫtகண  15. ம|தாரகண   
6. ைலtகண 16. வஷகண 
7. பரளtகண 17. ஊ¢கண  
8. ழிகண  18. «tகண  
9. ஆமகண 19. ெகாதி~©கண 
10. வறyசிகண 20. ேதைரகண  
6.ப«ன பாலவாகட எ§ ¥ ² 18 வைகக 
ப}வ¯மா² 
1. ரtகைண                        10. ச{திtகைண 
2. நலtகைண 11. ெர{தtகைண 





5. வரyசிtகைண 14. வாேல|திரகைண 
6. ெவ~©tகைண 15. வால ச|திரtகைண 
7. அனகைண 16. 
மேக|திரகைண 
8. வ uகைண 17. உ¶ ேராககைண 
9. மா|தகைண 18. மxசகைண 
 
7.T.V.சாபசிவபைள அகராதி பாக II  26 வைகக  
1. மா|தtகண   14. வரyகண  
2. «ttகண 15. ெகாதி~©கண  
3. ஊ{¢tகண 16. பறவகண   
4. ழிகண 17. மகாகண  
5. ைலகண 18. வ tகtகண  
6. ஆமகண 19. ேபாƫtகண  
7. ¬லகண 20. எƬகண  
8. ytகண 21. ர{தகண  
9. வாதகண 22. ம|தாரகண  
10. ப{தகண 23. அ|தகtகண  
11. சிேல{¢கண 24. ஊ¢மா|தகண  
12. நƫகண 25. வஷமா|தகண  
13. பரளகண 26. ேதைரtகண  
 
8.ஜவரyசாமிƫத எ§ ¥ ² 8 வைகக ப}வ¯மா² 
1. லிகண 5. மகாகண 
2. «tகண 6. ழிகண 
3. ஆமகண 7. 
கழிகண 
4. ேதைரகண 8. வரகண 
 
       என கண{திz வைகக பலவாறாக ற~பyள¢. 
 
கண{தி} ெபா¢tணuக  
ழ|ைதt மா|த ேநா பல«ைற வ|¢ அ¢ «றி´ 
ணமைடயாம உடப} உபதியேலேய இ¯|¢ «றி 
இ¯~பதனா உzடா. 
 வய² ேநாº  
 நா ேவtகாடா 
 ேம ¬v  
 கƫ கƫ எ§ ஒலி­ட} இ¯ம உzடா  
 உட இைள{த  
 ெபா²{¢~ ெபா²{¢ ர கா­   
ேம´  
 கzண} இயைக நிற மாறி காண~ப  
 கz ெவ¯z பாƫ{த  
 உvசிய ழி வ¸த  
 ெதாzைட கம  
 «க{தி சிறி¢ வயƫைவ உzடாத 
 வய² கழித , காத  
எ}பைவ கண{தி} ெபா¢tணuக ஆ. 
இைவய}றி , 
 வா உல¯ ; நƫ ேவyைக உzடா  
 ேபதியா ; மல எzெண கசிºளதாக இ¯t 
 சில ழ|ைதக¶t சதீமாகº , இர{தமாகº சதீ« , 
இர{த கல|¢ ேபதியா  
 மல த|¢ , நƫ ¯uகி­ இ¯{த 
 மாƫப அதிக ர , பசி{த ைறத 
 
ஆமகண 
ஆமகண எ}ப¢ அேயா{திதாசƫ பாலவாகட ¥லி 
றி­ள 24 வைககள ஒ}² ,  
ேநா ேதா}² வய¢ : 3 –12 வய¢  
 
ஆமகண{தி} ெபா¢tணuக  
 “ ஆம கண{தி} ணuேகளா 
  அைடவைட வாக ேவ¢பா¢  
  சாம| ேதா² ெவ¢ப நி  
  தzணƫ உழைல உzடா  
  ேசம{ ¢ட மிகஇைளt  
  சறீி ய¸ேம பசியைல  
  நாம| தள¯ இ¢தா§  
  நuகி ய¯tu கzடாேய  
  ழிt ெபா¯« வயறிழி­  
  வாச மிகº உzடா  
  க¸{ைத நாணt காtளƫ|¢  
  கzைண ¬ வழியா¢ 
  அ¸{த மான ர|ேதா}²  
  அயƫ|¢ சறீி{ தி¯tெக}§  
  ழிt ஆம கணெம}²  
  ெசா}னாƫ அரனாƫ ேதாைகtேக “ 
   (இ¢ºம¢) 
 “ எ}ேற ஆம ணuேக¶ 
  இனதா ெநx தா}¢t  
 வzேட சி²நƫ மxசநிற  
  வைகயா ©ைக­ ேமக~©  
 கzட உட© நிறேவறா 
  கணமா வ|ேத ஒ¯ேவைள  
 ந}றா ®த சƫவாuக    
  நலமா ேநாத மிxெம}ேற 
 மிx வயறி இைரvச´ட}  
  மிகº தைலய ேனாவாத  
 கxச ¬t ேமெல¸© 
 கனமா வாச மிகெவ¸ப 
  ¢x உட© ேமவரz{  
 ¢¯© ேபாேல வெவt  
  ெகx ஆம கணமி¢தா}  
 ேகளா ய|ேநா ஓராzேட” 
       (ெச­ –73) 
 ர உடலி ேதா}² . அvர ஏ²வ¢ இறuவ¢மாக  
இ¯~பேதா ஒெவா¯ சாம வy ஒெவா¯ சாம 
காவ¢மாக இ¯t. 
 தzணƫ ேவyைக உzடா  
 உட© மிக இைளt  
 சறீிv சறீி அ¸ ; பசி ஏபடா¢  
 வய² ேபதியா  
 ேம ¬v உzடா  
 சி²நƫ மxச நிறமாயறuக 
 அதிகமாக தைலேநா  
 அதிகமான ேம¬v உzடா 
 உட© இைள{¢ ¢¯© ேபாலா    
இவா² கணமான¢ கண| ெதாடƫதƬய ஆz இ¯|¢ 1 
ஆz வைரt ெதாடƫவதா. 
 
ைவ{திய சாரசuகிரக{தி ற~பyள ஆம கண{தி} 
றிணuக  
 சாம|ேதா² உட ெவ¢ப நா¶t நா ேதக 
இைளt  
 தாக மி ; பசி ம|திt  
 வய² ெபா¯மி இைர|¢ கழி­  
 வாசமி ; கா ள¯  
 ழ|ைத கz வழி|¢ அய², திtகிy எ¸|¢ சறீி அ¸  
 ©¯வx ழிt  
 
கƫ~பண பாலேராக சிகிvைசய ற~பyள ஆம கண{தி} 
றிணuக 
 “ ேபாெம}ற ஆமகண ண{ைதt ேகளா  
  ெபா¯மிேய சதீர{த பர|¢ கா   
   ஆெம}ற வாச வழி கழி{த காvச  
  அவயறி வலிேவƫைவ க¸|¢ நாண  
   ஓெம}ற ¬tெவ|¢  திtெக} ேறநா} 
  உைல|ெத¸|¢ ைககா´u ளƫ|¢ கா   
   நாெம}ேற கz¬ வழி{திடா¢ 
  நலி|¢ேபா ம¯|ததt நயமாtேகேள ” 
 வய² உ~பசமாகிvசதீ« ர{தமாக வய² கழி­  
 வாச , கz ெசா¯க  
 ர , அ வயறி வலி , வயƫைவ  
 க¸{¢ சிறி¢ இ¸{¢ ெகாள  
 திெர}² பய|¢ பtைகய இ¯|¢ எ¸த  
 கzகைளஎ~ேபா¢திறtகாம¬இ¯|த«தலியறிககா
ண~ப அ¢ “ஆமகண” என~ப.  
 
«tற ேவ²பாக 
 வாத, ப{த, கப ஆகிய ¬}² உயƫ தா¢tக மி, 
ைறநிைலய உzடா ேவ²பாக ேநா 
உப{தியாகிற¢ எ}² சி{த ம¯{¢வ ¥க ²கிற¢. 
 உணº வைகய மிதி­ ஐய{ைத உzடாகtய உணº 
ெபா¯yகைள உzபதா´,ளƫகாறி இ¯{த இவறா 
ஐயtற த}னைல மி|¢ வள அல¢ தtற அல¢ 
அவ¯ றuகேளா  ¬t, ெதாzைட, ¤ைரயர 
இவறி தாபத{ைத உzடாtகி ேகாைழைய­ , இ¯ம, ர 
«தலிய றிணuகைள பற~பt. 
 உட நிைலகள மாƫபடமான “ அநாகத{தி” எ¸ 
“ேமேநாtuகா” த} அளவ மி|¢ நி. 
 இ|ேநா­zடாவத «தகாரண ஐயtறேமெயன றி, 
ஐயமான¢ ¬v உ²~©கள} உளடuகள  
அைட{¢tெகாz காைற இயைகயாக இயuக ெவாyடாம 
த{தேல காரணெமனt றி இ¯~பேதா வளற« 
காரண என சி{த ம¯{¢வ ¥க றி உள¢. 
 ஆனா ஆம கண உzடாவத «tறuக¶ ய 
காரணமா. அவ² றி~பாக வள­ ஐய« ேசƫ|த 
மிதிேய காரணமாக அைமகிற¢.  
 
நா: 
உடலி உயƫ தƬ{தி¯~பத காரணமான சtதி எ¢ேவா 
அ¢ேவ “தா¢”அல¢ “நா”என~ப. 
 
நாேதாற  
 தசநாக¶ வா­tகளா உதவ ©Ƭய~பy த{த 
ெதாழிகைள~ ©Ƭகி}றன. அவ² ஏ¸ நtகி «tகியமானைவ 
¬}² ¬லாதார நாகளாகிய இடகைல, பuகைல, ழி«ைன 
எ}பைவயா. 
 இடகைல + அபான} = வாத  
 பuகைல + பராண} = ப{த  
 ழி«ைன+ சமான}  = கப  
 இவாறாக வாத,ப{த,கப எ}ற ¬}² நாக¶ 







பராண}  ¬v வாuக , வத 
ெச­,©சிt,உணºக
ைள ெசƬtக~ பz    
பாதி~© (ேம 
¬v உzடா )  
அபான}  மலசல{ைத த¶, 











உதான}  ேபvt «தகாரண 
«யசி, மேனாதிடப 
உzடாt   
பாதி~©(இ¯ம,ேம
 ¬v,) 






















இ¯|¢ நைர வழ~ 
பz   
இய© 















வ uகி~ பz . 
இற|¢வ} 
காெறலா 
ெவள~பyட ப}னƫ 3 
வ¢ நாள தைல 
















































அவலபக  ¤ைரயரலி இ¯|¢ 
மற  ஐயuகy 
ப²t ேகாடா 
இ¯t 
பாதி~© ( ¬v 
வட சிரம)  










தபக  கzக¶t இய© 
ளƬvசிைய உz~ 
பz  








காƫகால - ஆவண, ©ரyடாசி ( August to October) 
திƫtகால  - ஐ~பசி , காƫ{திைக (October to December 
) 
«}பனtகால  - மாƫகழி, ைத ( December to February ) 
ப}பனtகால - மாசி, பuன (February to April ) 
இளேவன கால  - சி{திைர , ைவகாசி ( April to June ) 









வாத  «¢ேவன  காƫகால திƫtகால 
ப{த  காƫகால திƫtகால «}பனtகால 




 இத} அ~பைடய ஆமகண திƫ கால{தி (ஐ~பசி , 
காƫ{திைக) ளƫ|த காறா´ , «}பன (மாƫகழி, ைத) ப}பன 
காலuகள (மாசி,பuன) பனயா´ ேதா}² ேநாயா. 
 ஆம கணமாவ¢ றி~பாக கப{தா ேதா}²கிற¢ . 
 கபமான¢ த}னைல சிறப©² கால – காƫ{திைக மாத 
«த மாசி மாத வைர. 
 இத} ¬ல இ|ேநா ஆன¢ திƫ கால «த  இளேவன 
கால வைர அதிகமாக காண~பகிற¢. 
 
ஐவைக நிலuக (திைண) 
றிxசி  - மைல­ மைல சாƫ|த இட«  
«ைல  - கா கா சாƫ|த இட« 
ம¯த  - வய´ வய சாƫ|த இட« 
ெநத  - கட´ கட சாƫ|த இட« 
பாைல - மண´ மண சாƫ|த இட« 
 
 ஆம கண{தி ேதƫº ெசய~பyட ேநாயாளகள மிதியாக 
ம¯த  நில மtகளாக காண~பyடனƫ.ஏெனன பாைளயuேகாyைட 
ம¯த நில~ பதியா.     
 
பணயறி«ைறைம  
 பணயறி«ைறைம எ}ப¢ உடைல~ பண{தலாய ேநாைய{ 
ெதƬ|¢ ெகா¶கிற ஒ¸tக என~ப.  
 
அைவ, 
1. ெபாறியா அறித  
2. ©லனா அறித 
3. வனாத  
4. எzவைக{ேதƫº 
 
1. ெபாறியா அறித  
¬t  - ¬tகி நƫ வத  
நா - இய©  
கz - இய© 
ேதா  - இய© 
ெசவ - இய© 
 
2. ©லனா அறித 
ைவ - ர இ¯|தா ைக~©  
ஒள  - இய© 
ஊ² - ெவ~ப  
ஓைச  - இய© 
நாற  - இய© 
3. வனாத  
 ேநாயாளய} ெபயƫ, வய¢, ெதாழி, ேநா ஏபyட வரலா², 
ேநாtகான «த}ைம காரண ஆகிய இைவகைள வனாத ¬ல 
ேகy அறிய~ப.  
 
4.எzவைக{ேதƫº: 
 “ நா பƬச நாநிற ெமாழி வழி  
   மல ¬{திரமிைவ ம¯{¢வரா­த”  






1. நா  
2. பƬச  
3. நா  
4. நிற  
5. ெமாழி  
6. வழி  




1. நா - ழ|ைதகள நா நைட ெகாz 
ேநாயைன கணtக இய´த ச² 
கனமானதா. ஏெனன 
ழ|ைதகள நா நைட சƬயாக 
ேதா}றா¢ எ}பைத  
 
“ெகாzடேவ கயேராகி காசேராகி  
 றி~பாக சிறி}ப ெசத ேபƫக  
 ஆzடேவ தƬ{தரƫக வ¯{தƫ 
பாலƫ 
 ெகாzடேவ இவƫகள உ²~ப} 
தா¢  
 றேவ «யா¢ எவƫtt கிy..” 
       (சி{த ம¯{¢வ ேநா நாட 
ேநா «தனாட திரy பாக –1)     
ஆம கண{தி வாதகப நா, ப{தகப 
நா, கப ப{த நா காண~பyட¢ 
2. பƬச
  
- ேநாயைன ெதாy பாƫ{தலி} ேபƬ, 
ேதாலி} ெசாரெசார~© த}ைம, 
உடகாuைக, மி¯¢ த}ைம, வயƫ{¢ 
உலƫத, வ tக, த~© இைவகைள 
பƬசி{¢ உணரலா.  
ஆம கண{தி ெவ~ப ர{தி} 
காரணமாக காண~பyட¢.                    
3. நா  - நாவ} நிற, ©z, வளƫvசி, பº 
இவைற கவனtக ேவz.  
ஆம கண கzட ழ|ைதக சிலƬ} 
நாவ} நிற ெவளறி காண~பyட¢.                    
4. நிற  - ேதாலி} நிற வாத, ப{த, கப 
இவறி} றிக¶ட} காணலா. 
ஆம கண கzட ழ|ைதக சிலƬ} 
உட நிற ெவளறி காண~பyட¢.                    
5. ெமாழி  - வாத ேநாயாளt சமஒலி­, ப{த 
ேநாயாளt உயƫ|த ஒலி­, ஐய 
ேநாயாளt இ}னைச ேபா}ற ஒலி­ 
இ¯t. 
ஆம கண{தி ¬vைச வட சிரம 
உளதா ர ஒலி  தா|¢ 
காண~பyட¢. 
6. வழி  - கzண கா  நிற, ஒள, பைள, 
வழி­ நƫ இவைற கவனtக 
ேவz.  
ஆம கண கzட ழ|ைதக சிலƬ} 
கீழிைமைய நtகி பாƫ{ததி ெவ¶{¢ 
காண~பyட¢. 
7. மல  - நிற,  ¤ைர , இ²க , இளக 




- நிற, மண , ¤ைர , எxச, எைட 
ஆம கண கzட ழ|ைதக சில¯t 
சி²நƫ மxச நிறமாயறuக. 




 “ வ|த நƫ கƬஎைடமண ¤ைர எxசெல} 
  ைற|திய´ளவைவ யைற¢ «ைறேய”  
-(ேநாநாடேநா«தனாடதிரyபாக–1) 






ஆமகண{தி எtற த}னைல மி|¢ள¢ எ}பைத 
ேநாயாளய} சி²நƬ ெநtறி ேசாதைன ெசவத} ¬ல 
அறியலா. 
 “அரெவன நzன ேக வாத  
  ஆழிேபாபரவ} அேத ப{த  
 «{ெதா{¢ நிகி} ெமாழிவெத} கபேம”. 
- (ேநா நாட ேநா «தனாட திரy பாக –1) 
ஆம கண கzட ழ|ைதக சிலƬ ேமாதிர ேபா}² பரவ­ 
மிக பல¯t «{¢ ேபா}² காண~பyட¢. 
 
ஏ¸ வைக உடதா¢tக 
 
உடகyக ெசயக  
ஆம கண{தி 
காண~ப நிைல 
சார  உடைல­, 
மனைத­ 
ஊtக«றv ெசவ¢  
பாதி~©(உடேசாƫ
º, மன ேசாƫº) 











ெகா¸~©  ெந~© பைச ஊy 
உதவ ©Ƭ­   
பாதி~© (உட 
ெமலிº) 









tகில /  
ேராணத 
க¯ ேதாற{தி 
«தலா நிப¢  
- 
 
ஆம கண{தி சார, ெச|நƫ, ஊz, ெகா¸~© பாதி~பைட|¢ள¢. 
 
ம¯{¢வ வழி«ைற 
 த}னைல வளƫvசியைட|த ஐய{ைத­, ப{த{ைத­ 
சம~ப{த ேவz . 
 ேவ²நிைல வளƫvசியைட|த வாத{ைத­ த}னைல~ ப{த 
ேவz. 
 வ}ைம இழ|த உடகyகைள வ}ைம அைடயv ெச­ 
வைகய ம¯|¢ அளtக ேவz. 
 
ம¯{¢வ: 
ஆம கண{தி வாசேடாƬ ரண  
அளº  : 500 மி.கி – 1 கி வைர 3 ேவைள 
அ§பான : ேத} 
ழ|ைதகள} ேதக நிைல, வய¢, கால நிைல, எைட, உயர, 
ேநாய} த}ைம ஆகிய இைவகைள ெபா²{¢ ம¯|தி} அளº 
நிƫணயtக~பyட¢. 
ெபா¢வாக கீகா  அளºகள ம¯|¢ தர~பyட¢. 
 வய¢  : 3 -5 வய¢ –500 மி.கி 
      5 -7  வய¢  - 1 கி 
    7- 12 வய¢ - 2 கி 
 
ப{திய: 
 “ ப{திய{தினாேல பல§zடா ம¯|¢  
   ப{தியuக ேபானா பல} ேபா – ப{திய{தி 
   ப{தியேம ெவறி த¯ பzதƫt ஆதலினா  
   ப{தியேம உ{தி ெய}² பாƫ “  
- ேதைரயƫ 
ம¯|¢z  காலuகள ேநாயாளகள} ேநாய} த}ைம 





 கண ேநாயாளக¶t ஆ கறி வவர: 
 “ கz ெகாவாƫ கறிவைகt வவர ேக¶ 
   கதலி­ட காயா «¯uைக~ பx  
   கz சி²கீைர ெநலிtகா தானா  
   தtக ¢வைர அவைர­ட பxமா   
   பz ெந பா ககz £¢ளuகா ஆ 
   பƬவான «ய´ப} இைறvசியா 
   ெகாzட} ெவளா ெவெளலி­ 
 ள{தி´ள வரா மசிறியா “ 
- மதைலேநா ெதாதி  
வளtக : 
 வாைழtகா, «¯uைக~பx, ெநலிtகா, ¢வைர, அவைர~ 
பx, £¢ளuகா, ெந, பா, ககz, «ய இைறvசி, உ© 
இைறvசி, ெவெளலி, வரா ம}, மிசிறி ம}. 
 இைவ கண ேநாயாளக¶t ஆ உணº பதாƫ{தமா. 
ஆகா ப{திய:     
 “ க நறில{ ெதzெண பாzடu கடைல  
   வ¯வதாகிய ெதuமா வ¯tைக நகாய 
   மவ லாதெவ ¶ளெகா ©ைகயைன ம¢ெபz 
   இட¢ பாகேவா டக{தி நி{¢டவv சாப{திய. 
     -ேதைரயƫ ெவzபா  









ேநா த~© «ைற ம² ம¯{¢வ அறிºைர: 
 ேநாயாளக தனt ஒவாத ெபா¯yகைள கzடறி|¢ அதைன 
நtக ேவz. 
 காதாரமற உணº வைகக ம² நƬைன தவƫtகº  
 ளƫகா², பனகாறி ெவளய ெசவைத தவƫtகº 
 உணவைன இளxy உzண ேவz  
 இரவ உணைவ சtீகிர உz சிறி¢ ேநர ெச}ற ப} 
உறuக ெசல ேவz. 
 ேநா எதிƫ~© சtதிைய த¯ ச{¢ள உணºகைள உzண 
ேவz (எ.கா.) எ´மிvைச, ஆரx, ெநலிtகா 
 ©Ƭ|¢ெகா¶ வயதி´ள ழ|ைதக¶t பராணாயாம 
ேபா}ற எளய ¬v~ பயசி «ைறகைள க² த¯த 
ேவz. 
 ெசல~ பராணகளான நா, ªைன இைவக¶ட} ெந¯uகி 
ப¸வைத தவƫtக ேவz 
 கப ேநா உளவƫக சிறிvசபாய உறuகலா எ}² 
ற~பyளன.    
 
சிறிvசபா : 
 “ சிறிv~ பாய றின« ப~பவ¯t 
   றிேம கா|த ´ட©வ¯x – கறியேதாƫ 
   வா­º² ப{தம² ம² கப|த¯| 
   தாயகமா மிtண{ைத சா² ” 
- அக{தியƫ ணபாட  
REVIEW OF MODERN LITERATURE 
 
According to the above said Siddha literatures about Aama Kanam, it reveals 
that Aama kanam is a disease associated with respiratory tract. Fever, Cough, 
Dyspnea, Wheezing were the predominant symptoms mentioned by various Siddhars. 
So it should be a respiratory infectious disease.  Hence, the author has compared the 
symptoms of Aama kanam which more or less correlates with the symptoms WALRI 
– Wheeze associated lower respiratory tract infection in modern medicine.  
 
ANATOMY OF RESPIRATORY TRACT 
In humans, the respiratory tract is the part of the anatomy involved with the 
process of respiration. The respiratory tract is divided into the upper 
airways and lower airways. The upper airways or upper respiratory tract includes 
the nose and nasal passages, paranasal sinuses, the pharynx, and the portion of 
the larynx above the vocal cords. The lower airways or lower respiratory tract includes 
the portion of the larynx below the vocal cords, trachea, bronchi andbronchioles. The 
lungs can be included in the lower respiratory tract or as separate entity and include 
the respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli. 
 
RESPIRATORY TRACT 
   
    Upper respiratory tract Lower respiratory tract 
 Nose   Larynx below vocal cords 
 Nasal passages  Trachea 
 Paranasal sinuses  Bronchi 
 Pharynx  Bronchioles 
 Larynx above the vocal cords  Lungs 













The Upper Respiratory Tract 
The upper respiratory tract, can refer to the parts of the respiratory system lying 
above thesternal angle (outside of the thorax), abovethe glottis (vocal cords), or above 
the cricoid cartilage. The larynx issometimes included in both the upper and lower 
airways.The larynx is alsocalled the voice box and has the associated cartilage that 
produces sound. The tract consists of the nasal cavity and paranasal sinuses  
,the pharynx (nasopharynx,oropharynx and laryngopharx) and sometimes includes the 
larynx. 
 
The Lower Respiratory Tract 
The lower respiratory tract or lower airway is derived from the 
developing foregut and consists of the trachea, bronchi (primary, secondary and 
tertiary), bronchioles (including terminal and respiratory), and lungs 
(including alveoli).  It also sometimes includes the larynx. 
 
Respiratory Tree  
The respiratory tree or tracheobronchial tree is a term also used to refer to the 
branching structure of airways supplying air to the lungs and includes the trachea, 
bronchi and bronchioles. 
 
The trachea 
It is the largest tube in the respiratory tract and consists of tracheal 
rings of hyaline cartilage. It branches off into two bronchial tubes, a left and a right 
main bronchus. The bronchi branch off into smaller sections inside the lungs, 
called bronchioles. These bronchioles give rise to the air sacs in the lungs called 







They are the largest organs in the lower respiratory tract. The lungs are 
suspended within the pleural cavity of the thorax. The pleurae are two thin 
membranes, one cell layer thick, which surrounds the lungs. The inner (visceral 
pleura) covers the lungs and the outer (parietal pleura) lines the inner surface of the 
chest wall. This membrane secretes a small amount of fluid, allowing the lungs to 
move freely within the pleural cavity while expanding and contracting during 
breathing. 
The lungs are divided into different lobes. The right lung is larger in size than 
the left, because of the heart's being situated to the left of the midline. The right lung 
has three lobes (upper, middle, lower)and the left lung has two lobes (upper and 
lower), plus a small tongue-shaped portion of the upper lobe known as the lingula. 
Each lobe is further divided into segments called bronchopulmonary segments.  
 
RIGHT LUNG  
1. Superior Lobe  Apical 
   Posterior  
   Anterior  
2. Middle Lobe  Lateral  
   Medial 
3. Inferior Lobe  Superior ( apical) 
   Medial basal 
   Anterior basal 
   Lateral basal 





LEFT LUNG  
1. Superior Lobe  Apical 
   Posterior  
   Anterior  
   Superior lingular 
   Inferior lingular  
2. Inferior Lobe  Superior ( apical) 
   Medial basal 
   Anterior basal 
   Lateral basal 
   Posterior basal  
 
Each lung has a costal surface, which is adjacent to the ribcage; a 
diaphragmatic surface, which faces downward toward the diaphragm; and a 
mediastinal surface, which faces toward the center of the chest, and lies against the 
heart, great vessels, and the carina where the two mainstem bronchi branch off from 
the base of the trachea. 
 
Bronchi 
A bronchus, also known as a main or primary bronchus, is an airway in 
the respiratory tract that conducts air into the lungs. There is a right bronchus and a 
left bronchus and these bronchi branch into smaller secondary and tertiary bronchi 
which branch into smaller tubes, known as bronchioles. 
 The right and left primary branches are formed by the division of the trachea at 
the level of T4 vertebra just behind the sternal angle. The right bronchus is wider, 
shorter and more vertical than the left so right bronchus is the more common sites for 















Each tertiary bronchus conduct, air to and form a bronchopulmonary segment.  
 All conducting and respiratory passage ways distal to the primary bronchi are 
found with in the lungs.  
 
Bronchioles 
The bronchioles or bronchioli are the passageways by which air passes through 
the nose or mouth to the alveoli (air sacs) of the lungs, in which branches no longer 
contain cartilage or glands in their submucosa. They are branches of the bronchi, and 
are part of the conducting zone of the respiratory system. The bronchioles divide 
further into smaller terminal bronchioles which are still in the conducting zone and 
these then divide into the smaller respiratory bronchioles which mark the beginning of 
the respiratory region. 
The primary bronchi, in each lung, which are the left and right bronchus, give 
rise tosecondary bronchi. These in turn give rise to tertiary bronchi (tertiary meaning 
third). The tertiary bronchi subdivide into the bronchioles. 
 
Terminal bronchioles 
The terminal bronchiole is the most distal segment of the conducting zone. It 
branches off the lesser bronchioles. Each of the terminal bronchioles divides to 
form respiratory bronchioles which contain a small number of alveoli. 
Respiratory bronchioles 
The primary Bronchi 
Secondary Bronchi(Lobar Bronchi) 
Tertiary Bronchi(Segmental Bronchi) 
Smaller Bronchi 
The respiratory bronchioles are the narrowest airways of the lungs, one fiftieth 
of an inch across.The bronchi divide many times before evolving into the bronchioles. 
The bronchioles deliver air to the exchange surfaces of the lungs.They are interrupted 
by alveoli which are thin walled evaginations. Alveolar ducts are distal continuations 
of the respiratory bronchioles. 
 
Blood supply  
 The Bronchial arteries supply nutrition to the bronchial tree and to the 
pulmonary tissue. The venous blood is carried by the bronchial vein. 
 
Lymphatic drainage 
 There are two sets of lymphatics both of which drain into broncho pulmonary 
nodes. 
 
Nerve supply  
 Parasympathetic nerves are derived from the vagus.  Sympathetic nerves are 
derived from the spinal segments T2 to T3. 
 
Peculiarities of respiratory tract in children  
 Chest wall is thin, elastic, yielding and intrinsic muscles are weak 
 Short thorax with the ribs running more horizontally 
 Increase in Antero posterior diameter of the chest with limited inspiration  
 Epiglottis is longer and projects backwards at a greater degree than in older 
children.  
 All these peculiarities tend to increase the risk of permanent deformity in the 
chest wall in the presence of recurrent or long standing respiratory distress. By above 
8 years the chest assumes conical shape since the antero posterior diameter is less than 




WALRI(Wheeze associated lower Respiratory tract Infection) 
 
DEFINITION  
 Inflammation of the breathing tubes within the lungs (bronchial tubes or 
bronchi) as a result of an infection (viral or bacterial) or a chemical irritant (such as 




a. Viral (Primary) 
i. Adeno virus 
ii. Rhino virus 
iii. Influenza virus 
iv. Para influenza virus type 1 and 3  
b. Bacterial ( Less common)  
i. Staphylococcus aureus 
ii. Streptococcus pneumonia 
iii. Escherichia  coli  
 
 
c. Fungus  
Very rarely a infection caused by fungus can cause WALRI.  
2. Physical and chemical irritants  
a. Inhales dust (especially dust mite ) 
b. Poisonous gases – smoke, damaging fumes from factories 
c. Pollen or organic dusts 
3. WALRI is commonly associated with the following conditions  
a. Influenza  
b. Measles 
c. Whooping cough 
d. Typhoid fever 
4. Some basic underlying causes are 
a. Sinusitis 
b. Bronchiectasis  
c. Congenital heart disease  
5. Pre disposing factors  
a. Allergy 
b. Over crowding  
c. Under nutrients  
d. Chronic upper respiratory infection  
6. Premature birth: Babies who are premature (born too early) may be at higher 
risk for bronchitis. 
 
PATHOPHYSIOLOGY  
WALRIleads to the hacking cough that often follows upper respiratory tract 
infection. This occurs because of the inflammatory response of the mucous membrane 
within the lungs. Viruses, acting alone, account for most of these infections.  
Mucociliary clearance is an important primary innate defence mechanism that 
protects the lungs from the harmful effects of inhaled pollutants, allergens, and 
pathogens. 
The mucociliary apparatus consists of 3 functional compartments: the cilia, a 
protective mucus layer, and an airways surface liquid layer, which work together to 
remove inhaled particles from lungs. 
The most common bacterial pathogen that causes lower respiratory tract 
infections in childrenof all age groups is Streptococcus Pneumonia. Nontypeable 
Haemophilus influenza may be significant pathogens in pre-schoolers(age<5year), 
Mycoplasma Pneumoniamay be significant in school aged children(ages 6-17years) 
 
CLINICAL FEATURES OF WALRI  
1. Expectorating cough 
It is an important symptom of WALRI 
 The cough is initially frequent, dry, non-productive and graduated onset. 
 Cough is preceded by rhinitis (3 – 4 days) 
 Within several days the cough from clear to purulent (Greenish, or 
yellowish mucus) and occasionally is flacked with blood 
 Within 5 – 10 days the mucus become thin and the cough disappears 
gradually 
2. Shortness of breath (dyspnoea) 
3. Wheezing 
4. Malaise  
5. Chest Pain 
 Occasionally on breathing deeply or coughing  
6. Fever 
7. Head ache 
8. sore throat and a runny or stuffy nose 
9. Tiredness more than usual. 
PHYSICAL EXAMINATION 
 Lungs may sound normal.  
 Crackles, rhonchi, or large airway wheezing, if any, tend to be scattered and 
bilateral.  
 The pharynx may be injected. 
 
DIAGNOSIS  
 A physical examination will often reveal decreased intensity of breath sounds, 
wheezing, rhonchi, and prolonged expiration.  
 A chest X-ray is useful to exclude pneumonia which is more common in those 
with a fever, fast heart rate, fast respiratory rate, or who are old.  
 Sputum examination  
 A sputum sample showing Neutrophil granulocytes (inflammatory white 
blood cells)  
 Sputum culture showing that has pathogenic microorganisms such 
as Streptococcus species. 
 Blood test 
 Raised white blood cell count  
 Elevated C-reactive protein 
 Pulmonary function test  
 
COMPLICATIONS 
 Chronic bronchitis  
 Bronchopneumonia 
 Acute respiratory failure 
 Bronchial asthma 
 Sinusitis  
 Otitis media  
DIFFERENTIAL DIAGNOSIS  
 Chronic bronchitis  
 Pneumonia  
 Bronchial asthma 
 Tuberculosis  
 
DELAY RECOVERY CONDITION  
 Heart / other lung diseases. 
 Living in an area with air pollution 
 Other health problem  
 
PREVENTION 
 Avoid cold, allergens, polluted areas 
 Get vaccinated 
 Wash your hand 
 Eat healthy foods 
 Wear a mask over your nose and mouth 
 Regular exercise  
  
MATERIALS AND METHODS 
 
SELECTION OF CASES 
The cases were selected according to the signs and symptoms mentioned in the 
siddha text. And certain criteria were found for the selection of patients. In 20 cases 
were treated in OP 20 cases were treated in IP. According to severity. 
 
INCLUSION CRITERIA:  
 Age : 3 – 12 years 
 Sex : Both male and female children. 
 Fever with intermittent rise of temperature 
 Wheeze 
 Thirst 







EXCLUSION CRITERIA:  
 Children above 12 years. 
 Cough with haemoptysis. 
 High grade fever. 
 Any malignancy  
 Dyspnoea associated with cyanosis and clubbing. 
 Abdominal distension due to any other serious illness. 
 Sudden reduction of weight. 
 Status Asthmatics. 
 
WITHDRAWAL CRITERIA: 
 If any adverse reactions & altered symptoms occurred during the drug trial. 
 Intolerance to the drug.  
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness. 
 
DIAGNOSIS 
1.Siddha diagnosis was made with the help of following methods 
 Poriyaal arithal 
 Pulanaal arithal 
 Vinathal  
 Envagai thervugal (Including neerkuri, neikuri) 
 Udal thathukkal 
 Paruva kaalam (Season) 
 Thinaigal  
 
2.LAB INVESTIGATION  
I.Blood 
 TC                                                   
 Differential WBC count 
 Neutrophils  
 Lymphocytes  
 Eosinophils 










 X-RAY Chest PA View  
 Sputum Culture 
 
SELECTION OF DRUGS AND ITS ADMINISTRATION  
 The trail drugs are selected from, Agasthiyar vaithiyakaviyam 1500 
 The trail medicine is Swasakudori chooranam  
 The medicine process the ability to bring dhoshaas in equilibrium and 
having mainly anti inflammatory, expectorant, anti pyretic actions, to 
relieve the spasm and to expel the sputum. 
 
DRUG REGIMEN  
Swasakudori chooranam  ½ g to 2g with adjuvant honey thrice a day after 
meals.  
The dosage of medicine with different age group 
3  to 5 years - 500mg  
5 to 7 years - 1g 
7 to 12 years - 2g 
 Biochemical analysis of the trial drugs were done at the Department of 
Biochemistry , Government Sidhha Medical College, Palayamkottai. Pharmacology 
analysis of the trail drugs were done at K.M.College of Pharmacy, Department of 
Pharmacology, Madurai. Anti microbial study was also done and the details are given 
in the annexure.    
 
CASE PROFORMA  
  The symptoms and signs of Aama kanam, history of present and past illness, 
personal history, nutritional history, family history, immunization history, laboratory 







 PREPARATION AND PROPERTIES OF TRIAL MEDICINE 
 
NAME OF THE MEDICINE –SWASAKUDORI CHOORANAM (INTERNAL) 
REFERENCE BOOK  –AGASTHIYAR VAITHIYA KAVIYAM 1500 
 
வாசtேடாƬ ரண 
ேதைவயான சரtக  
1. t (Zingiber offcinale) - 17.5gm 
2. மிள (Piper nigrum) - 17.5gm 
3. தி~பலி (Piper longum) - 17.5 gm 
4. சிறர{ைத (Alpinia officinarum) - 17.5gm 
5. அtகரகார(Anacyclus pyrethrum) - 17.5gm 
6. வாமிள (Piper cubeba) - 17.5gm 
7. ேமா (Piper longum) - 17.5gm 
8. ெவuகார (borax) - 17.5gm 
9. தாளசப{திƬ (Abies spectabilis) - 280 gm 
 
ெச«ைற: 
 ேமகzட சரtகைள தன தனேய «ைற~ப {தி ெச¢, 
இ{¢, சலி{¢ அத} ப} வதிரகாய ெச¢ எ{¢ ெகாள 
ேவz.    
 
 
 “ ரணமாx வாசெம}ற ேடாƬ த}ைனv 
  yகிேற} திƬக சிறர{ைத  
 ரணமா வtராகார வாமிள  
  ெசாலƬய ேதசா©ர ெபாƬகாரxசமனா  
 ரணமா தாளசப{திƬ ெரy y  
  Ƭய ©ட{தி ன´லƫ{தி £ளாயாy 
 ரணமா வகy கல|¢ ©¢tகரக{ 
  £yவாய §பானx ெசாலt ேகேள ”  
 
அளº: 
 5௦௦ மி.கி «த 2 கி (வயதி த|தாேபா) 






 3 மாதuக  
“ உயƫ ரணபy வடகெவz ெணநா}கி  
 §யƫ¬}² திuகளா ” 







Botanical Name : Zingiber officinale 
Family  : Zingiberaceae 
பய}ப 
பாக  
: கிழu ( உலƫ|த¢ ) 
ண : ைவ - காƫ~©, த}ைம – ெவ~ப, பƬº 
– காƫ~©  
ெசைக  : ெவ~ப«zடாtகி –Stimulant     
பசி{த{£z     -Stomachie 
அகyவாவகறி –Carminative  
{தி  : t “©ற நx” 
ேமேதா நtகிட {தியா   
ெபா¢ண  : “ைலம|த ெநxெசƬ~© ேதாடேம~ 
பமழைல 
 ¬ல இைர~ப¯ம ¬tநƫ – 
வாலகப  
 ேதாடமதி சார| ெதாடƫவாத }மநƫ{  
 ேதாடஆ மேபாtv t “ 
 
 
ெசƬயாைம, மாƫ© எƬvச, இைர~©, 
இ¯ம, கழிvச, நேரற, }ம, 
வய²~பச, ஐயர ேபா  
Constituents  : Analgesic, Sedative, Antipyretic   
Antibacterial 
properties  
: Sesquiterpenoids ( β -  sesquipnellandrene, 
bisabole and farnesene) 
Monoterpenoid fraction  ( β – phelladrene, 
cineolcitro)  






Anti – emetic  
 
2. மிள  
Botanical Name : Piper nigrum 
Family  : Piperaceae 
பய}ப பாக  : வைத  
ண : ைவ - ைக~©, காƫ~©, த}ைம – 
ெவ~ப; பƬº –காƫ~©   
ெசைக  : கார´zடாtகி  -Acrid 
அகyவாவகறி –Carminative  
«ைறெவ~பகறி  -Antiperiodic  
த~©zடாtகி   -Rubefacient 
ெவ~ப«zடாtகி  -Stimulant  
வ tகuகைரvசி     -Resolvent  
வாதமடtகி        -Antivatha 
நvசƬ             - Antidote 
ெபா¢ண  : “தயாக எu திƬ­மைத யாவ{¢  
ேமாயாம ெல~ப­ «zடாtகா – 
பாயா¢  
வள, த, கபtறuக இைவ 
அைன{த­ நt. அ}றி­ 
திமிƫவாத, கழைல, வள, சள 
இைவகைள­ அக²   
     (ேதர} ெவzபா)    
Constituents  : Piperine , Alkamides, Piptigrine, Wisanine, 
Dipiperamide, 50 – 60 % inhibitory activity on 
Acrtylcholinesterase 
Properties : Anti-oxidant , Anti inflammatory  
3. தி~பலி 
Botanical Name : Piper longum 




ண  : ைவ - இன~©; த}ைம – தyப ; பƬº – 
இன~©  
ெசைக  : ெவ~ப«zடாtகி  - Stimulant 
அகyவா­அகறி –Carminative 
ெபா¢ண  : “ஈைள ய¯ம லிைர~©~ பசி~பனக 
மான ெவாழியாம வாyேம – 
யாள«ைற 
பாuகா யறி|¢ெசவ ƫ பzத{ைத~ 
பzதேர  
ேவuைகவா~ பா}கைண ெம” 
ஈைள, இ¯ம,இைர~©, உ~பச «தலிய 
பணகைள~ ேபாt. 
Constituents  : Piperine, Piperidine, Pipernonaline, 
Piperundecalidine 




Botanical Name : Alpinia officinarum 
Family  : Zingiberaceae 
பய}ப 
பாக  
: ேவƫ  
ண : ைவ –காƫ~© ; வ Ƭய – ெவ~ப; பƬº – 
காƫ~©  
ெசைக  : ேகாைழயகறி - Expectorant 
ெவ~பகறி        -Febrifuge 
பசி{த{£z - Stomachic 
ெபா¢ண  :  தைலேநா, சதீள, இ¯ம, ர 
நu 
 சிறர{ைதைய வாயலிy ைவ{¢ 
வர  ெதாzைடய கy ேகாைழ, 
வா|தி, இ¯ம தண­ 
Constituents  : Flavonoids  






5. அtகரகார  
Botanical Name : Anacyclus pyrethrum 
Family  : Asteraceae 
பய}ப 
பாக  
: ேவƫ  
ண : ைவ –காƫ~© ; த}ைம – ெவ~ப; பƬº – 
காƫ~©  
ெசைக  : ெவ~ப«zடாtகி – Stimulant  
உமிநƫெப¯tகி  - Sialogogue 
த~©zடாtகி       - Rubefacient 
ெபா¢ண  : நாவறyசி, ெதாzைடகம நu  
Constituents  : Anacyclin, Pellitorine, Hydrocarolin 











6. வாமிள  
Botanical Name : Piper cubeba 
Family  : Piperaceae 
பய}ப 
பாக  
: உலƫ|த «திராத கா  
ண : ைவ –காƫ~© ; த}ைம – ெவ~ப; பƬº – 
காƫ~©  
ெசைக  : அகyவாவகறி –Carminative  
ெவ~ப«zடாtகி  -Stimulant  
ேகாைழயகறி     - Expectorant 
சி²நƫ~ெப¯tகி   -Diuretic 
ெபா¢ண  : “ வாதப{த ஐய வய² வலிதாகx 
  சதீ பலேநா சிைத­uகாz-ேபாத  
  அதித பனமா அனuகரேச நா¶| 
  ¢திவா மிளக¯|தv ெசா”  
இதனா வள, த,ஐயuறuக¶, 
}ம, நƫேவyைக, ெவைள «தலியன 
ேபா. பசி உzடா.   
Constituents  : Piperine , Alkamides, Piptigrine, Wisanine, 
Dipiperamide, 50 – 60 % inhibitory activity on 
Acrtylcholinesterase 





7. ேமா (தி~பலி ேவƫ) 
Botanical Name : Piper longum 
Family  : Piperaceae 
பய}ப 
பாக  
: ேவƫ  
ண : ைவ –காƫ~© ; த}ைம – ெவ~ப; பƬº 
– காƫ~©  
ெசைக  : பசி{த{£z–Stomachic 
ெபா¢ண  : கழிvச, ர, நாyபyட இ¯ம, 
இைர~©, வா|தி, அ{தி ர நu   
Constituents  : Piperidine, Pipernonaline  














English Name : Borax, 
ண : ைவ : இன~©ட} ய ¢வƫ~©  
ெசைக  : ளƫvசி உzடாtகி –Refrigerant  
சி²நƫ~ெப¯tகி     -Diuretic 
¯¢ºzடாtகி      -Emmenogogue  
பரசவகாƬ          -Parturifacient  
ககைரvசி          -Lithontriptic 
உடேதறி         -Tonic 
அ¸கலகறி        -Antiseptic  
{தி  : ெவuகார{ைத நƫவ²ப ெபாƬ{¢t 
ெகாzடா {தி.   
ெபா¢ண  : “ெசாறி©ைடெயz }மநைம ெசாƬ 
யாச  
பறிகிரண கµன ப}ேனா – 
ெநைய{ 
தடuகணuக பuகி¯மி சƫ~பவடx ச|தி  
யடuகணuக லtகிேபா ெமz”  
தவைளvெசாறி, }ம, தினº, பேநா, 
கபாதிtக, ச|திபாத ©¸, பா© 
«தலியைவகளா உzடாt நx.  
 
9. தாளசப{திƬ 
Botanical Name : Abies spectabilis 
Family  : Pinaceae 
பய}ப பாக  : இைல 
ண : ைவ –காƫ~© ; த}ைம – ெவ~ப; 
பƬº – காƫ~©  
ெசைக  : பசி{த{£z         - Stomachic 
அகyவாகறி  - Carminative 
ேகாைழயகறி      - Expectorant 
உரமாtகி                  - Tonic  
ெபா¢ண  : கழிvச, ர, நாyபyட இ¯ம, 
இைர~©, வா|தி, அ{தி ர நu   
Constituents  : Piperidine, Pipernonaline  








ண : ைவ – இன~© ; நிற – இளமxச  
ெசைக  : உளழலாறி      
















ெபா¢ண  : அவத பலிtக ேவzமானா 
அ§பான~ ெபா¯ ேதைவ எ}பைத­, 
அவ§பான~ ெபா¯க¶ ேத§ 
ஒ}² எ}பைத­  
“அ§பான{ தாேல யவத பலிt 
இனதான t }னலிxசி – ப§«தகu   
 ேகாமய பா «ைல~பா ேகாெநேத}   
ெவறிைல நƫ  
ஆமிைதயா ரா|¢ ெசயலா” 
-ணபாட தா¢ சவீ வ~© 
எ}ற ெச­ளா உணரலா. 
ேத} அ§பான~ ெபா¯ளாவத}றி அவத~ 
ெபா¯¶மாகி ேதக{ைத ந}னைலய 
ைவ{¢, வாத «தலிய ¬}² 
றuகைள­ ேபாt எ}பைத ேதர} 
²கிறாƫ. 
ேதைனபான ெச¢ வ|தா கப~பணக 
நu.   
Constituents  : Honey is mainly a mixture of dextrose ( grape sugar) 
and levulose ( fruit sugar). It also contains wax, 
Volatile oil, mucilage, coloring matter, formic acid , 
ash, ethereal oil, phosphates,   calcium, iron, fat 
soluble, water  soluble vitamins and a special protein.  
 
  
   
Zingiberoffcinale  Alpiniaofficinarum  
  
Piper nigrum  Anacyclus pyrethrum  
  
Piper longum  borax  
  








OBSERVATION AND RESULTS 
 





































    Out of 40 cases 7.5 % of cases belong to age group 1-3 years,   37.5  % of cases 
belong to age group of 3-6 years, 30   % of cases belong to age group of 6-10 years 
and  25% of cases belong to age group 10-12 years. 
 
 
0-1 Year 1-3 Years 3-6 Years 6-10 Years 10-12 Years

















S.No Age No of cases Percentage 
1. 0-1 Year 
Kappu and  Chenkeerai 
- - 
2. 1-3 Years 
Thalattu, Sappani, Muttham, Varugai 
3 7.50 
3. 3-6 Years 
Ambuli,Chitril,Chiruparai,Chiruther, 
Paethai(female) & Pillai(male) 
15 37.5 








S.No Sex No of cases Percentage 
1. Male 22 55% 







       Among 40 cases of study 22 were males (55%) and 18 were females (45%), males 









S.No Religion No of cases Percentage 
1. Hindu  28 70 
2. Muslim  4 10 












S.No Informant No of cases Percentage 
1. Mother 29 72.50 
2. Father 7 17.50 
3. Grand parents 4 10 






According to this 72.50  % of cases were good reliability, 17.50  % of cases 







S.No Food Habit No of cases Percentage 
1. Vegetarian  10 25 
















6.SOCIO ECONOMIC STATUS 
 
S.No Socio Economic Status No of cases Percentage 
1. Poor  28 70 
2. Middle class 12 30 






      Out of 40 cases   70  % belong to poor socio economic class and   30 % belong to 
middle class. 
  
7. DISTRIBUTION OF PARUVAKAALANGAL: 
S.No Paruvakaalangal No of cases Percentage 
1. Kaar(Aavani,Purattasi) (August 
to October) 
- - 
2. Koothir (Ayppasi,Karthigai) 
(October to December) 
10 25 
3. Munpani (Markazhi,Thai) 
(December to February) 
12 30 
4. Pinpani (Maasi,Pankuni) 
(February to April) 
7 17.5 
5. Elavenil (Chitthirai,Vaikasi) 
(April to June) 
11 27.5 
6. Muthuvenil (Aani,Aadi) 





      Out of 40 cases   30 % of cases came during Munpanikaalam, 27.5 % of cases of 
the incidence come under the Elavenilkaalam, 25 % of cases of the incidence come 
under the Koothirkaalam, 17.5 % of cases of the incidence come under the 
Pinpanikaalam.The prevalence of disease under Munpanikaalam and Pinpanikaalam. 
 
8. DISTRIBUTION OF THINAIGAL (LANDS) 
S.No Thinai No of cases Percentage 
1. Kurinji (Hill) - - 
2. Mullai (Forest) - - 
3. Marutham(Fertile) 38 95 
4. Neithal (Coastal) 2 5 






 According to Siddha concept, no disease occurs to the people living in 
marutham, but todays people entirely differs from their ancestors both in dietary and 
other habits. And also the study was conducted in and around Tirunelveli. A 
marutham land.So, Majority of cases in from the land. 
 
 9.CLINICAL FEATURES 
S.No Signs and Symptoms  No of cases Percentage 
1. Cough with Expectorating 25 62.5 
2. Sneezing  7 17.5 
3. Fever 35 87.5 
4. Headache 15 37.5 
5. Wheezing  30 75 
6. Sore throat  16 40 
7. Running nose 11 27.5 
8. Yellow color urination 3 7.5 
9. Weight  loss 2 5 
10. Loss of appetite  15 37.5 
11. Constipation  8 20 




 According to clinical features fever has highest percentage as 87.5 % , 75 % of 
Wheezing and weight loss has lowest percentage as 5%. 
 
10.UYIR THATHUKKAL 
a. Derangement of  Vatham 
 
S.No Type of vatham  No of cases Percentage 
1. Pranan ( ) 40 100 
2. Abanan  20 50 
3. Viyanan  - - 
4. Uthanan  40 100 
5. Samanan  40 100 
6. Nagan  - - 
7. Koorman  10 25 
8. Kirukaran  30 75 
9. Devathathan  15 37.5 





 According to this Pranan, Uthanan, Samanan  has 100 %,  Kirukaran has 75% 
and koorman have lowest percentage as 25%.  
 
b. Derangement of Pitham  
S.No Type of pitham  No of cases Percentage 
1. Analagam ( ) 24 60 
2. Ranjagam  15 37.5 
3. Saathagam  40 100 
4. Pirasagam  8 20 







 According to this saathagam has 100, Analagam has 60 %, ranjagam has 37.5 
% and Pirasagam has 20%. 
 
c. Derangement of Kabam  
S.No Type of kabam  No of cases Percentage 
1. Avalambagam  40 100 
2. Kilethakam  30 75 
3. Pothakam  - - 
4. Tharpakam  - - 






 According to this Avalambagamhas 100% and Kilethakam has 75%. 
 
 
11. UDAL KATTUGAL  
 
S.No Udal Kattugal No of cases Percentage 
1. Saaram  40 100 
2. Senneer  15 37.5 
3. Oon  20 50 
4. Kozhuppu  20 50 
5. Enbu  - - 
6. Moolai  - - 








 According to this Saaram has 100%, Oon and  Kozhuppu have 50 % and 
Senneer has 37.5%. 
12. ENVAGAI THERVUGAL  
S.No Udal thathukkal No of cases Percentage 
1. Naadi  
a. Vatha kaba naadi 20 50 
b. Pitha kaba naadi 15 37.5 
c. Kaba pitha naadi 5 12.5 
2. Sparisam  30 75 
3. Naa  16 40 
4. Niram  10 25 
5. Mozhi  04 10 
6. Vizhi  - - 
7. Malam  10 25 




 According to this sparisam has highest percentage as 75% ,Moothiram have 55 
% and mozhi have 10 % as lowest value. 
13. NEIKURI  
 
S.No Character of urine Neikuri reference No of cases Percentage 
1. Spreads like serpent Vatha neer 10 25 
2. Spreads like ring Pitha neer 4 10 





 According to this Kaba neer have 65 %, Pitha neer have 10 %  and  Vatha neer 
have 25 %. 
  
14. OUTPATIENTS RECORDS 
 
S.No. OP No. Name Age/ sex 
No. of days 
treated 
Remarks 
1 107910 Ranjini 4 1/2FC 40 Good 
2 108724 Dhavship 4MC 40 Good 
3 109179 Jeni 12FC 36 Good 
4 110074 Hariram 8MC 25 Good 
5 110670 Muhamadyath 12MC 36 Good 
6 110757 Abdul Ajith 4MC 30 Good 
7 111963 Karthika 8FC 16 Moderate  
8 473 Raji 7FC 21 Good 
9 2043 Shafia 7FC 40 Good 
10 4073 Ramina 6FC 28 Good 
11 6826 Inaya 3FC 15 Mild 
12 7912 Lakshmanan 5MC 20 Moderate 
13 8349 Renuga 11FC 35 Good 
14 9117 Eswar 4MC 18 Good 
15 9118 Muthiah 6MC 20 Good 
16 9224 Sri 10MC 25 Good 
17 9955 Amalainiyam 9MC 15 Moderate 
18 533 Sham 12MC 18 Good 
19 11042 Rehana 3FC 28 Good 
20 12108 Abirami 12FC 20 Good 
15. Case reports of twenty cases for the diseases – Aama kanam 
















Total no of 
days treated Result 
1 3388 Karthika 7/FC 28.12.15 
Cough with 
expectoration, 
Difficulties in breathing 
, Wheeze,  Constipation 
11.01.16 1 month 15 days Good 
2 3389 Balasutharsan 3/MC 28.12.15 
Fever ,Running nose,  
Cough with 
expectoration,Wheeze, 
Lose of appetite 
11.01.16 10 days 15 days Good 
3 834 Dalphin 7/MC 28.03.16 
Cough with 
expectoration, 
Difficulties in breathing 
, Wheeze,  Sneezing, 
Lose of weight 
23.04.16 1 year 35days Good 
4 898 Muthia 4/MC 02.04.16 
Fever, Headache, Sore 
throat, Cough with 
expectoration, Wheeze,  
Constipation 
14.04.16 20 Days 13 days Moderate 




09.04.16 20 days 7 days Mild 
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6 991 Durkesh 4/MC 11.04.16 
Fever ,Running nose,  
Cough with 
expectoration,Wheeze, 
Loss of appetite. 







Difficulties h breathing 
in night time, Wheeze   
05.05.16 1 month 25 days Good 
8 1008 Mano 12/FC 14.04.16 
Fever ,Running nose,  
Cough with 
expectoration, Loss of 
appetite, Constipation 
26.04.16 7 days 13 days Good 
9 
1145 Mugesh 6/MC 29.04.16 
Cough without 
expectoration, Sore 
throat, loss of appetite, 
Yellow color urination, 
Sneezing, Wheeze   
18.05.16 1 week 20 days Good 
10 1243 Mathuleka 12/FC 10.05.16 
Fever, Sneezing, 
Headache, Running 
nose, Cough with 
expectoration, Sore 
Throat 
21.05.16 10 days 12 Days Good 






27.05.16 3 months 18 Days Good 




Difficulties in breathing 




Fever, Cough without 
expectoration, Yellow 
color urination, Wheeze 
27.05.16 2 Months 18 days Good 
14 1254 Harini 5/FC 11.05.16 
Fever, Cough without 
expectoration,Wheeze, 
Headache, Running 
nose,loss of appetite 
01.06.16 15 days 21 days Good 
15 1265 Jenirose 9/FC 13.05.16 
Fever, Sore throat, 
Cough without 
expectoration, 
loss of appetite 
26.05.16 2 weeks 10 days Good 





Difficulties in breathing 
27.05.16 20 days 15 days Good 
17 




Difficulties in breathing 
27.05.16 4 days 9 days Moderate 79 
18 1332 Akshya 4/FC 20.05.16 
Cough without 
expectoration, Wheeze 
Difficulties in breathing 
at night time 
01.06.16 15 days 12 days Good 




Fever, Cough without 
expectoration, 
Headache, 
loss of appetite 
03.06.16 8 days 11 days Good 
20 1390 Ashwinkumar 8/MC 26.05.16 




























X – ray chest 






Hb /gm % 
WBC differential count / cu.mm mm /hr 
BT AT 
BT AT 
BT AT BT AT BT AT 
BT AT BT AT P% L% E% P% L% E% 
1 3388 Karthika 7/FC Nor Nor -Ve -Ve 8600 8700 50 46 4 44 45 1 670 320 20 09 9.1 10 
2 3389 Balasutharsan 3/MC Nor Nor -Ve -Ve 8300 7960 60 38 2 52 42 6 360 280 14 09 11 12 
3 834 Dalphin 7/MC Bro Nor -Ve -Ve 7000 8500 55 42 3 56 43 1 1460 670 22 10 9.2 10.8 
4 898 Muthiah 4/MC Nor Nor -Ve -Ve 9500 9100 60 35 5 64 31 5 Nil Nil 8 07 11 12 
5 913 Sankar 5/MC Nor Nor -Ve -Ve 9100 8950 50 46 4 60 37 3 520 410 13 10 12.3 13 
6 991 Durkesh 4/MC Nor Nor -Ve -Ve 8000 7500 52 40 8 44 43 3 440 380 10 08 11 12.2 
7 992 Srichithambar
am 
10/MC Nor Nor -Ve -Ve 9800 9500 80 17 3 67 32 1 Nil Nil 14 10 9.1 11 
8 1008 Mano 12/FC Nor Nor -Ve -Ve 8600 8500 65 31 4 61 37 2 Nil Nil 16 10 12.8 13 
9 1145 Mugesh 6/MC Nor Nor -Ve -Ve 9050 8910 56 40 4 60 39 1 1260 560 8 05 9.8 10.5 
10 1243 Mathuleka 12/FC Nor Nor -Ve -Ve 9000 9100 55 42 3 56 43 1 728 480 10 nil 12 13 
 
BT – Before Treatment ; AT – After Treatment ; P – Polymorphs ; E – Eosinophils ; ESR – Erthrocyte Sedimentation ; HB – Haemoglobin ; WBC – White blood cell ; 















X – ray chest 






Hb /gm % 
WBC differential count / cu.mm mm /hr 
BT AT 
BT AT 
BT AT BT AT BT AT 
BT AT BT AT P% L% E% P% L% E% 
11 1244 Shofika 5.5/FC Nor Nor -Ve -Ve 9100 8950 49 46 5 39 57 4 Nil Nil 10 05 10.8 12 
12 1245 Maharaja 1/MC Nor Nor -Ve -Ve 7500 7000 54 42 4 58 40 2 250 230 48 20 10.3 11 
13 1246 Karthiyayini 12/MC Nor Nor -Ve -Ve 8000 8200 64 33 3 66 33 1 340 320 30 14 11.2 12.1 
14 1254 Harini 5/FC Nor Nor -Ve -Ve 8600 8400 52 44 4 56 43 1 Nil Nil 20 08 9.2 10 
15 991 Jenirose 9/FC Nor Nor -Ve -Ve 11500 9800 45 40 15 50 45 5 435 324 36 nil 10 11 
16 992 Deniyal 8/MC Nor Nor -Ve -Ve 7500 8000 58 40 2 60 39 1 Nil Nil 6 06 10 12 
17 1008 Sharvika 4/FC Nor Nor -Ve -Ve 12800 9500 70 27 3 67 32 1 Nil Nil nil nil 9 11 
18 1145 Akshya 4/FC Nor Nor -Ve -Ve 8000 7500 50 38 6 54 42 4 370 350 18 10 10.6 11.2 
19 1243 Madhu 12/MC Nor Nor -Ve -Ve 9000 9100 53 40 7 50 46 4 290 280 12 08 11.8 12 
20 1244 Ashwinkumar 8/MC Nor Nor -Ve -Ve 8600 8300 65 31 4 60 38 2 Nil Nil 16 10 13.8 14 
 
BT – Before Treatment ; AT – After Treatment ; P – Polymorphs ; E – Eosinophils ; ESR – Erthrocyte Sedimentation ; HB – Haemoglobin ; WBC – White blood cell ; 

















Urine Analysis Motion analysis 
BT AT BT AT 
Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1 3388 Karthika 7/FC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
2 3389 Balasutharsan 3/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
3 834 Dalphin 7/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
4 898 Muthiah 4/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
5 913 Sankar 5/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
6 991 Durkesh 4/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
7 992 Srichithambaram 10/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
8 1008 Mano 12/FC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
9 1145 Mugesh 6/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
10 1243 Mathuleka 12/FC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
11 1244 Shofika 5.5/FC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
12 1245 Maharaja 1/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
13 1246 Kathiyayini 12/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
14 1254 Harini 5/FC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
15 991 Jenirose 9/FC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
16 992 Deniyal 8/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
17 1008 Sharvika 4/FC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
18 1145 Akshya 4/FC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
19 1243 Madhu 12/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
20 1244 Ashwinkumar 8/MC Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil 
 




Among 40 cases, the results were observed 
S.No Results  No of cases Percentage 
1. Good 33 82.5 
2. Moderate 5 12.5 




 82.5 % showed good response, 12.5 % showed Moderate response and 













Aama Kanam is one of the common diseases, affecting the pediatrics 
age group. This disease has been clearly described in several Siddha text.   
It occurs due to exposure to cold, dust, fumes, pollens, mental stress 
and taking allergic food. The primary factory which is involved in “Aama 
kanam” is kaba.   
Aama kanam signs and symptoms are more or less related with acute 
bronchitis (WALRI – Wheeze Associated Lower Respiratory Tract Infection) 
In this study, 20 cases were diagnosed at OP according to the clinical 
features in Siddha text. Out of 40 cases, 20 patients were selected and 
admitted in PG – Kuzhanthai Maruthuvam. IP ward, Government Siddha 
Medical College, Palayamkottai. 20 patients were treated in outpatient 
department. 
Siddha method diagnosis were carried out and recorded in performa 
with the help of modern investigation. The patients were treated with the drug 
“SWASAKUDORI CHOORANAM” and results were observed. The 
observations are discussed here under.   
The observations are discussed below, 
 
DISTRIBUTION ACCORDING TO AGE 
 This study indicates that children’s under the age group of 3-6 years 
(37.5 %) are mostly affected. Since they contribute to school going age they 
may be exposed to a variety of allergens. 
 
DISTRIBUTION ACCORDING TO SEX 
 Among 40 cases of study 55 % were male children and 45 % were 





DISTRIBUTION ACCORDING TO RELIGION 
 Out of 40 cases 70 % were Hindus, 20 % were Christians and 10 % 
were Muslims. 
 
INFORMANT   
 According to this 72.50 % of cases were good reliability, 17.50 % of 
cases were fair reliability and 10 % of cases were not reliability.  
 
DIET HISTORY 
 According to diet history 75 % of cases were had mixed diet and 25 % 
of cases had vegetarian diet. The highest incidence of cases was observed in 
mixed diet of food habits. 
 
DISTRIBUTION ACCORDING TO SOCIO ECONOMIC STATUS 
 Most of the patients 70 % were belonged to low income group, 30 % 
were belonged to middle class group. Due to poverty, malnutrition, 
overcrowding and Unhygienic practices this disease is more prevalent among 
the poor.  
 
DISTRIBUTION OF LAND  
         Among the selected 5% of them were from Neithal land 95% of them 
were from Marutham land. 
 
DISTRIBUTION OF PARUVAKAALANGAL 
According to paruvakaalam the highest distribution 30 % was noticed 
in munpanikaalam, 27.5 % was noticed in ElavenilKaalam, 25 % was noticed 






DISTRIBUTION ACCORDING TO AETIOLOGICAL FACTORS 
 Dust, respiratory infections and cold exposures were the main 
aetiological factors among the children.  
 
DISTRIBUTION OF CLINICAL FEATURES  
Before treatment maximum cases 87.5% were present with fever,  70% had 
wheezing,  62.5% patient had cough with expectoration,  37.5% patient had 
cough without expectoration,  40% had sore throat,  27.5% of them had 
running nose,  17.5% had sneezing and 20% had incidence of constipation. 
 
DISTRIBUTION ACCORDING TO UYIR THATHUKKAL 
a. Derangement of Vatham 
 Due to derangement of vathamPranan, Uthanan, Samanan were 
affected in all the 100 % of the patients. Kirukaran was affected in 75 % of the 
patients Abanan was affected in 50 % of the patients. Devathathan was 
affected in 37.5 % of the patients and Koorman was affected in 25 % of the 
patients.  
 
b. Derangement of Pitham 
 Due to derangement of pitham, Saathgam was affected in all the 100 % 
of the patients. Analagam was affected in 60 % of the patients. Ranjagam was 
affected in 37.5 % of the patients.  Pirasagam was affected in 20 % of the 
patients.   
 
c. Derangement of  Kabam 
 Due to derangement of Kabam, Avalambagam was affected in all the 






DISTRIBUTION ACCORDING TO UDAL KATTUGAL 
 According to UdalKattugal ,Saaramwas affected in all the 100 % of the 
patients. Oon and Kozhuppu were affected in 50%   of the patients. Senner 
was affected in  37.5 % of the patients.  
 
DISTRIBUTION ACCORDING TO ENVAGAI THERVUGAL 
 According to Envagaithervugal, Sparisamwas affected in 75 % of the 
patients. Moothiram was affected in 50 % of the patients. Naa was affected in 
40 % of the patients. Niram and Malam were affected in 25 % of the patients. 
Mozhiwas affected in  10 % of the patients.  
 
DISTRIBUTION ACCORDING TO NEIKURI 
 According to Neikurimost of the patients affected by Kabaneer as 65 
% of patients, Vathaneer as 25% and Pithaneer as 10%. 
 
LAB INVESTIGATION  
Routine examination of blood, urine, motion, weight and sputum were done 
before and after treatment. 
 
RESULT 
The clinical effort ofSwasakudori chooranamis discussed here. Out of 40 
cases 32 patients(80% )showed good response 5 patients(12.5%)showed 
moderate response 3 patients(7.5%) showed mild response. 
 
SUGGESTION 
Because of the encouraging results clinically, the study may be undertaken 
with the same drug for a prolonged period of  time in a large number of 







 The aim of this dissertation subject is to assess the efficacy of trial drug 
“Swasakudori Chooranam” for “Aama Kanam” without any adverse 
effects.   
 The Aama Kanam has been correlated with that of WALRI with 
evidence of literature. 
 Clinical diagnosis and selection of cases was based on clinical features 
described in Balavagadam text book. 
 The medicine chosen for treatment and management of Aama Kanam 
was Swasakudori Chooranam. ½ to 2gm (according to age) internally 
thrice a day. 
 The trial drug selection is based on its siddha pharmacological action to 
pacify the deranged vatham, pitham and kabam and also due to its 
immune modulatory and antipyretic,histamine effect of ingredients.  
 Forty children were diagnosed with Aama kanam clinically and they 
were observed for clinical diagnosis, laboratory diagnosis during the 
treatment and the results were dealt in the proforma. 
 Laboratory diagnosis was done by modern methods of examinations. 
 The documentation of observation made during the clinical study 
showed that the drug is clinically effective. 
 The biochemical study shows presence of calcium, tannic acid, 
unsaturation compound, amino acid in Swasakudori Chooranam.  
 Antimicrobial study shows that the medicine has got sensitivity to 
Escherichia coli, Streptococcus pnumoniae and moderate resistant to 
Staphylococcus aureus. 
 In the pharmacological analysis, the trial drug Swasakudori Chooranam 





 The treatment of Swasakudori Chooranam for Aama Kanam showed 
good response. 
 No adverse effect were noticed during the course of treatment  
 The trial medicine ingredients are easily available and harmless to 
children  
 The cost of the trial medicine is comparatively very slow. 
 
So it is concluded that the therapy of Swasakudori Chooranam can be very 




















































































ANNEXURE - II 
BIO-CHEMICAL ANALYSIS OF SWASAKUDORI CHOORANAM 
PREPARATION OF THE EXTRACT:  
 5gms of the drug was weighed accurately and placed in a 250ml clean 
beaker then 50ml of distilled water is added and dissolved well. Then it is 
boiled well for about 10 minutes. It is cooled and filtered in a 100ml 
volumetric flask and then it is make up to 100ml with distilled water.  This 
fluid is taken for analysis. 
QUALITATIVE ANALYSIS 
S.NO. EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared 
extract is taken in a clean 
test tube. To this add 2ml of 









2. TEST FOR SULPHATE 
2ml of the extract is added 








3.  TEST FOR CHLORIDE 
The extract is treated with 
silver nitrate solution 
 
No white 




4. TEST FOR 
CARBONATE 
The substance is treated 
with concentrated Hcl. 
No brisk 
effervescences is 





5. TEST FOR STARCH 
The extract is added with 
weak iodine solution 
 
No blue colour is  
formed 
Absence of starch 
6.  TEST FOR FERRIC 
IRON 
The extract is acidified with 
Glacial acetic acid and 
potassium ferro cyanide. 
 
No blue colour is 
formed 
Absence of ferric  
iron indicates the 
absence 
7. TEST FOR FERROUS 
IRON  
The extract is treated with 








8.  TEST FOR PHOSPHATE 
The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid 
 





9.  TEST FOR ALBUMIN 
The extract is treated with 
Esbach’s reagent 





10.  TEST FOR TANNIC 
ACID 








11.  TEST FOR 
UNSATURATION 
Potassium permanganate 










12.  TEST FOR THE 
REDUCING SUGAR 
5ml of Benedict’s 
qualitative solution is taken 
in a test tube and allowed to 
boil for 2 minutes and add 
8-10 drops of the extract 
and again boil it for 2 
minutes. 




13.  TEST FOR AMINO 
ACID 
One or two drops of the 
extract is placed on a filter 
paper and dried well. After 
drying, 1% Ninhydrin is 
sprayed over the same and 
dried it well. 
 





14. TEST FOR ZINC 





Absence of zinc 
 
Inference: The above analysis indicate the presence of calcium, Tanic acid, 




PHARMACOLOGICAL STUDIES  
 
1. ANTIHISTAMINIC AND ANTIANAPHYLACTIC ACTIVITY OF 
SIDDHA FORMULATION OF SWASAKUDORI CHOORANAM 
 
INTRODUCTION 
Allergy is one of the common diseases that affect mankind with diverse 
manifestations. The prevalence of allergy and asthma has risen in the recent 
years despite an improvement in the general health of the population. Allergic 
diseases are responsible for significant morbidity and have severe economic 
impact. Various epidemiological studies have identified the causes for an 
increase in the prevalence of upper and lower respiratory tract allergic 
diseases. Some of the postulated reasons are increasing environmental 
pollution  and increased predisposition of individuals producing excessive IgE 
through a major change in the gene pool, changing lifestyles, and an 
increasing awareness of the disorders. Intensive research during the last 
several decades has highlighted the role of lymphocytes, immunoglobulins, 
mast cells, and various autacoids in the etiopathogenesis of allergic conditions. 
Inspite of the voluminous literature on the subject, the treatment of allergic 
diseases continues to be far from satisfactory. The available treatment options 
for upper and lower respiratory tract allergic diseases have major limitations 
owing to low efficacy, associated adverse events, and compliance issues. 
 
AYUSH, an Indian system of medicine, has described several drugs 
from indigenous plant sources for use in the treatment of bronchial asthma and 
allergic disorders. In the present study, the effects of Siddha formulation of 
Swasakudori chooranam were studied on the active anaphylaxis and mast cell 





MATERIALS AND METHODS 
ANIMALS 
Inbred Wistar rats (175–200 g) and guinea pigs (400–600g) of either 
sex housed in standard conditions (temperature22 ± 2° C, relative humidity 60 
± 5% and 12 h light/dark cycle) were used. They were fed with standard pellet 
diet and water ad libitum. The Institutional Animal Ethics Committee 
approved the experimental protocol. Histamine and horse serum were 
procured from Sigma Chemicals and toluidine blue from Loba-Chemie, 
Mumbai. Elisa kit for IgE was supplied by Orion diagnostics, Espoc, Finland. 
All other chemicals and reagents were procured from Hi-Media Laboratories 
limited, Mumbai. 
 
MAST CELL STABILIZING ACTIVITY 
TREATMENT PROTOCOL 
Twenty-four rats were divided into four groups of six animals in each 
group.  
Group I : served as control and received vehicle (water). 
Group II : (sensitized control group) 
GroupIII : served as the treatment control, which was treated with 
Swasakudori chooranam  at a dose of 200mg/kg body weight, in oral route. 
Group IV : served as the treatment control, which was treated with 
Swasakudori chooranam at a dose of 400 mg/kg body weight, in oral route. 
 
In group11 to group 1V were sensitized by injecting 0.5 ml of horse 
serum subcutaneously along with 0.5 ml of triple antigen containing 20,000 
million Bordetella pertussis organisms (Serum Institute of India Ltd.,Pune), 
Once a day for 14 days.  
On day 14, the rats were sacrificed 2 h after the treatment and the 
intestinal mesentry was taken out for the study on mast cells. Mesentries along 
with intestinal pieces were excised and kept in Ringer Locke solution 
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(NaCl154, KCl 5.6, CaCl2 2.2, NaHCO3 6.0, glucose 5.55 mm/L of distilled 
water) at 37oC. The mesenteric pieces were challenged with 5% horse serum 
for 10 min after which the mast cells were stained with 1.0% toluidine blue 
and examined microscopically for the number of intact and degranulated mast 
cells. 
 
HISTAMINE-INDUCED BRONCHOSPASM IN GUINEA PIGS 
Bronchospasm was induced in guinea pigs by exposing them to 1% 
histamine aerosol under constant pressure (1 kg/cm2) in an aerosol chamber 
(24 × 14 × 24 cm) made of perplexGlass,of the three groups of six animals 
each. 
 
Group I :  Served as control. 
GroupII : Served as the treatment control, which was treated with 
Swasakudori chooranam at a dose of 200 mg/kg body weight, in oral route. 
Group III served as the treatment control, which was treated with 
Swasakudori chooranamat a dose of 400 mg/kg body weight, in oral route. 
 
The animals were exposed to 1% histamine aerosol under constant 
pressure (1 kg/cm2) in an aerosol chamber on day 0 without any treatment. 
The end point,preconvulsivedyspnea (PCD) was determined from the time of 
aerosol exposure to the onset of dyspnea leading to the appearance of 
convulsions. As soon as PCD commenced, the animals were removed from the 
chamber and exposed to fresh air. This PCD was taken as day 0 value. On 
days 1 and 5,2 h after the administration of the drug, the time for the onset of 
PCD was recorded as on day 0. 
 
STATISTICAL ANALYSIS 
The results of various studies were expressed as mean ± SEM and 
analyzed statistically using one-way ANOVA, followed by 
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Newmannkeul’smultiple range tests. P<0.05 was considered statistically 
significant.The analysis was performed using Graphpad Prism software 
package (Version 4.0). 
 
RESULTS 
Mast cell stabilizing potential of Swasakudori chooranam  Antigen 
challenge resulted in significant degranulation of the mesentric mast cells. 
Pretreatment of sensitized animals with Swasakudori chooranam at a dose of 
200mg/kg and 400mg/kg, p.o., for 2 weeks resulted in a significant reduction 
in the number of disrupted mast cells (P <0.001) when challenged with horse 
serum.  
 
EFFECT ON HISTAMINE-INDUCED BRONCHOSPASM 
Swasakudori chooranam at a dose of 200mg/kg and 400mg/kg p.o., 
significantly prolonged the latent period of PCD (P <0.001) as compared to 
control, following exposure to histamine aerosols on day 5 [Table no. 2]. 
 
DISCUSSION 
Experimental animal model of asthma is characterized by allergen-
induced immediate airway constriction and late airway reactivity to a 
pharmacological vasoconstrictor such as histamine and leukotrienes. 
Histamine is a central mediator in the pathogenesis of allergic and 
inflammatory disorders. In the present study, Swasakudori chooranam 
prolonged the latent period of PCD in guinea pigs following histamine aerosol. 
This may be suggestive of an antihistaminic activity following treatment with 
Swasakudori chooranam. 
 Antigen challenge, in sensitized animals, results in the degranulation of 
mast cells, which is an important feature of anaphylaxis. In the present study, 
Swasakudori chooranam showed marked protection against the mast cell 
degranulation following antigen challenge in sensitized animals. Mast cell 
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stabilizing activity of Swasakudori chooranam may be attributed to the 
presence of active constituents which are known for their mast cell stabilizing 
potential against antigen–antibody reaction and/or due to the suppression of 
IgE antibody production, which is responsible for degranulation mast cells. 
This antianaphylactic and antihistaminic effect may be caused by the 
stabilization of the mast cell membrane, suppression of IgE, and inhibition of 
pathological effects induced by the release of inflammatory mediators in 
Swasakudori chooranam treated animals. All the above findings lend credence 
to the beneficial use of Swasakudori chooranam  in the treatment of asthma 
and related conditions.However, further studies with other experimental 
models, especially to explore the role of cytokines are warranted to 
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2.ANTI – PYRETIC STUDY OF SWASAKUDORI CHOORANAM(By yeast 
method) 
INTRODUCTION 
The practice of herbal medicine dates back to the very earliest period of 
known human history. There is evidence of herbs have been used in the 
treatment of diseases and for revitalizing body system in almost all ancient 
civilization. Ayurveda, the Science of Life, has provided a rational basis for 
treatment of various ailments. Pain, inflammation and fever are very common 
complications in human beings.  
Pyrexia or fever is caused as a secondary impact of infection, 
malignancy or other diseased states; wherein there is abrupt increase the core 
temperature above the normal level (Math et al., 2011). It is the body’s natural 
defence to create an environment where infectious agent or damaged tissue 
cannot survive (Chattopadhyayet al.,2005). Normally the infected or damaged 
tissue initiates the enhanced formation of pro-inflammatory mediator’s 
(cytokines like interleukin 1a and TNF- a) which increase the synthesis of 
prostaglandin E2 (PGE2) near peptic hypothalamus area and thereby 
triggering the hypothalamus to elevate the body temperature (Spacer and 
Breder, 1994). The regulation of body temperature requires a delicate balance 
between the production and loss of heat. As the temperature regulatory system 
is governed by a nervous feedback mechanism, so when body temperature 
becomes very high, it dilates the blood vessels and increase sweating to reduce 
the temperature; but when the body temperature becomes very low 
hypothalamus protect the internal temperature by vasoconstriction. The 
hypothalamus regulates the set point at which body temperature is maintained. 
In fever this set point is elevated and a drug like paracetamol does not 
influence body temperature when it is elevated by factors such as exercise or 
an increase in ambient temperature (Ashokkumaret al., 2010). 
Several plants and their products are claimed and proved to possess 
antipyretic property (Nanda et al., 2009). Although the body surface 
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temperature is ordinarily measured in clinical practice, it is the body core 
temperature which is physiologically important. The rectal temperature (which 
reflects the core temperature closely) is about 0.6ºC higher than oral 
temperature and about 1.4ºC higher than axillary temperature. The generally 
accepted normal limits of rectal temperature in adults are 36.1ºC and 37.8ºC; 
the body temperature is higher in infants. If the core temperature rises by more 
than a few degrees in man, mental changes occur. It is well known that an 
individual with high fever is often confused and delirious. The working of 
many tissue enzymes is also adversely affected and hyperpyrexia may result in 
death. However, core temperature below 40.5ºC is generally tolerated by most 
individuals (Satoskaret al., 2010).  
A natural antipyretic agent with reduced or non- toxicity is essential. 
Further, as health care costs continue to escalate,  the attraction for low cost 
remedies has stimulated consumers to re-evaluate the potential of alternatives 
(Chattopadhyay and Arunachalam, 2005; Valarmathiet al.. 2010; Jaiswalet al., 
2011). Therefore the present study was undertaken to investigate the 
antipyretic properties of the Swasakudori chooranam.  
 
REQUIREMENTS: 
Animal                            : Wistar albino rats weighing about 180-200 g 
Drugs and chemicals          : Injection of 20 % w/v of brewer’s yeast (10 
ml/kg)                  
Swasakudori chooranam 
 
EXPERIMENTAL ANIMALS  
Wistar albino rats were weighed (180-200 g) were procured from 
K.M.College of Pharmacy,Madurai.. The animals were housed in the 
departmental animal house under standard conditions (26 ± 2°C and relative 
humidity 30-35%) in 12 hours light and 12 hours dark cycle respectively for 1 
week before and during the experiments. Animals were provided with 
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standard rodent pellet diet and had free excess of water. The composition of 
diet is 10% protein, 4% Arachisoil, 1% fibers, 1% calcium, 1000 IU/gm 
vitamin A and 500 IU/gm vitamin D. All the animals were acclimatized to the 
laboratory conditions prior to experimentation. All the experiments were 
conducted between 10.00 and 17.00 hr and were in accordance with the ethical 
guidelines of the CPCSEA. 
 
 TREATMENT PROTOCOL: 
Body weights of the animals were recorded and they were randomly 
divided into 5 groups of 6 animals each as follows: 
 Group I : Animals served as control normal saline 10 ml/kg) 
 
Group II  : Animals were treated with yeast via subcutaneous injection (10 
ml/kg).  
 
Group III  : Animals were administered with yeast (10 mL/kg) and the 
standard drug paracetamol  150 mg/kg b.w.), orally  
 
Group IV : Animals were administered with yeast (10 mL/kg,) and 
received 200mg/kg of Swasakudori chooranamdissolved with 2ml sterile 
water and administered through orally. 
 
Group-V :Animals were administered with yeast (10 mL/kg,) and received 
400mg/kg of Swasakudori chooranam dissolved with 2ml sterile water and 








ANTIPYRETIC ACTIVITY  
 
YEAST INDUCED PYREXIA METHOD  
A suspension of Brewer’s yeast (15%) in saline (0.9%) was prepared. 
Five groups, each containing 6 rats of either sex were taken. The thermocouple 
was inserted 2 cm deep into the rectum and the rectal temperatures were 
recorded. Pyrexia was induced by subcutaneous injection of 20% w/v of 
brewer’s yeast (10 ml/kg) in distilled water. The basal rectal temperature was 
measured before the injection of yeast, by inserting digital clinical 
thermometer to a depth of 2 cm into the rectum. The sight of injection was 
massaged in order to spread the suspension beneath the skin. The room 
temperature was kept at 22-24°C, immediately after yeast administration, food 
was withdrawn and the rise in rectal temperature was recorded. The 
measurement was repeated after 30 minutes. The dose of the test compound 
and standard drug was given orally. The rectal temperature was recorded again 
after 1, 2 and 4 hours. Paracetamol (150 mg/kg) was selected as a standard 
drug. The Swasakudori chooranam were dissolved in sterile water. The data 
were analyzed for significance using the one way anova followed by 
newmannkeuls multiple range tests.  
 
RESULTS 
The antipyretic potential of Swasakudori chooranam was evaluated by 
determining its effect on yeast-induced pyrexia in albino rats. Table.1 shows 
that animals treated with Swasakudori chooranampossess significant 
antipyretic property when compared with group 2 and also provided the 
highest marked antipyretic activities. The result showed the Swasakudori 
chooranamat a dose of 200 and 400 mg/kg caused lowering of the body 
temperature induced by injection of Brewer s yeast in the experimental 
animals significantly from 1 to 3 hrs following its administration. The effect of 
Swasakudori chooranam on yeast-induced pyrexia showed that the rectal 
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temperature was markedly elevated to 39.19°C, 3 hr after the subcutaneous 
injection of yeast suspension, decreased to 38.67°C within 3 hr of 
Swasakudori chooranam treatment respectively, and reduced till 3 hrs showing 
a sizeable decrease and was comparable to paracetamol at 150 mg/kg marked 
antipyretic activity detected which were significantly different than the 
controls (p<0.01).  The antipyretic activity was equal to that of the standard 
drug paracetamol. This result reveals that the Swasakudori chooranam has 
marked antipyretic activity as compared with standard paracetamol.  
 
Table.1 The Effect of Swasakudori chooranam on body  temperature in 




0hr 1hr 2hr 3hr 
Group I 
(Control) 
38.30 ± 0.8 37.52 ± 0.80 37.72 ± 0.80 37.60 ± 0.50 
Group II             
(10 ml/kg) 
41.50 ± 0.23 42.20 ± 0.18 39.32 ± 0.15 39.20 ± 0.26 
Group III                   
(150 mg/kg) 41.40 ± 0.19 39.65 ± 0.18 
38.48 ± 
0.23* 37.60 ± 0.38 * 
Group IV                  
(200 m/kg) 
41.60 ± 0.02 39.80 ±0.20 
39.40 ± 
0.16* 
38.62 ± 0.42 * 
Group V                  
(400 m/kg) 
41.25 ± 0.04 39.50 ±0.18 
39.00 ± 
0.18* 
38.60 ± 0.38 * 
 
Values are expressed as Mean ±SEM. n = 6 in each group,  






The Swasakudori chooranamshowed significant antipyretic activity. 
The animals were also fevered by injection of Brewer’s yeast suspension (10 
mL/kg) subcutaneously in back below the nape of the neck for the antipyretic 
activity. The extract showed significant decrease in elevated body temperature 
as compared to standard drug paracetamol. The possible mechanism of 
antipyretic action may be due to the inhibition of prostaglandin as that of 
paracetamol by blocking the cyclo-oxygenase enzyme activity 
(Chandrasekharan and Simmons, 2004). There are several mediators for 
pyrexia and the inhibition of any one of these can be responsible for the 
antipyretic effect (Rawlins and Karger, 1973). Inhibition of any of these 
mediators may bring about antipyresis.  
Antipyretics have been shown to suppress fever by inhibiting 
prostaglandin synthetase, resulting in the blockade of the synthesis of 
prostaglandin in the brain or suppressing the rise of interleukin-1α production 
subsequent to interferon production. The oral administration of Swasakudori 
chooranamwere significantly attenuated rectal temperature of yeast induced 
pyrexia in rats and comparable to that of standard drug paracetamol. So, 
inhibition of prostaglandin synthesis could be the possible mechanism of 
antipyretic action as that of paracetamol.  Also, there are several mediators or 
multiprocesses underlining the pathogenesis of fever.  Inhibition of any of 
these mediators may bring about antipyresis (Akilet al.,1998). Thus, it can be 
postulated that the Swasakudori chooranam contains pharmacologically active 
principles that interfere with the release of prostaglandins. This may be 
attributed to the presence of the various bioactive compound present in the 
Swasakudori chooranam which may be involved in inhibition of prostaglandin 
synthesis. Also, there are several mediators or multiprocessors underlining the 
pathogenesis of fever. Inhibition of any of these mediators may bring about 
antipyresis. Flavanoids like baicalin have been shown to exert antipyretic 
effect by suppressing TNF-α (Adesokanet al.,2008) and its related compounds 
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also exhibit inhibition of arachidonic acid peroxidation, which results in 
reduction of prostaglandin levels thus reducing the fever and pains (Germainet 
al., 2011). The present study also correlates with the study of Zakariaet al., 
(2007) that the compounds like flavonoids and saponins are suggested to act 
synergistically to exert the observed pharmacological activity. Flavonoids are 
known to target prostaglandins which are responsible for pyrexia 
(Rajnarayananet al., 2006). The presence of flavonoids in the Swasakudori 
chooranam may be contributory to its antipyretic activity. This potentiality 
supports the earlier traditional claims as a pediatric antipyretic remedy. 
 
CONCLUSION 
Herbal medicines derived from the plant  extracts are being 
increasingly utilized to treat a wide variety of clinical diseases, though 
relatively little knowledge about their mode of action is available. In 
conclusion, the present study provides evidences for the Swasakudori 
chooranamshows significant antipyretic activity which could partly contribute 
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TABLE NO:1 EFFECT OF SWASAKUDORI  CHOORANAMON MAST 
CELL STABILIZATION IN SENSITIZED RATS 
 Values are expressed as Mean±S.E.M 
       *a significantly different from sensitized control at p<0.01 
TABLE NO 2 : EFFECT OF SWASAKUDORI  CHOORANAM ON 
HISTAMINE INDUCED BRONCHOSPASM IN GUINEA PIGS. 
GROUPS 
PRE-CONVULSION DYSPNEA (PCD)(SEC) 
DAY 0 DAY 1 DAY 5 










180±6.30 218±8.0 418±13.5*a 
Values are expressed as Mean ±S.E.M 




Normal control 84.40±3.98 17.40±0.85 











To study the Antimicrobial action of “ Swasakudori Chooranam” by 
“paper disc agar diffusion method” (Kirby – bauyer method). 
 
MEDIUM 
 Muller Hinton Agar 
 
COMPONENTS OF MEDIUM  
Beef extract  - 300 g /lit 
Agar   - 17 g/lit 
Starch   - 1.5 mg/lit 
Casein Hydrolysate  - 17.5 g / lit 
Distilled water    - 1000 ml 




PREPARATION OF INOCULUM 
 The given microorganism is inoculated in 1ml of peptone water under 
sterile condition. The inoculum is incubated at 37˚C for 2 hrs then the turbidity 
of the inoculums is adjusted to 0.5µc farland turbidity standard. The inoculum 
was poured in a Muller Hinton agar plate and uniformly spreaded over the 
plate.  The excess inoculum was discarded.  
 
DISC PREPARATION  
 The known quantity of the given chemical compound is impregnated in 
a 6mm diameter filter paper disc and applied over the inoculum. Then the 
Muller Hinton agar plate is incubated at 37˚C for overnight. The 
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zoneclearance is measured with a scale and the sensitivity of the organisms to 
the given trail drug is assessed.  
The diameter of zone of inhibition was observed and recorded.  
 
TABULATION OF ANTIMICROBIAL ACTIVITY OF TRIAL MEDICINES 





























































GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
CONSENT FORM 
 
An open clinical study to evaluate the safety and efficacy of Siddha sasthric 
formulation “ Swasakudori Chooranam” for the management of Aama Kanam 
(WALRI) 
CERTIFICATE BY INVESTIGATOR  
I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent 
Date  : Signature  : 
Place : Name         : 
 
CONSENT OF INFORMANT  
I have been informed to my satisfaction, by the attending physician, the purpose of 
the clinical trial, and the nature of drug treatment and follow up including the 
laboratory investigations to be performed to monitor and safeguard my Son / 
Daughter body functions.    
I am aware of my right to opt out to tail at any time during the course of the trial 
without having to give the reasons for doing so. 
        I am exercising my free power of choice, here by give my consent to be 
included as a subject in the clinical trial of “ Swasakudori Chooranam” for the 
treatment of Aama Kanam (WALRI) 
 
Date   :  Informant Signature   :  
Place  :  Patient Name             :  
Signature of 
witness : 
 Informant Name  :  




GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PROFORMA OF CASE SHEET FOR AAMA KANAM 
 
 
IP. No. :  Religion :  
Bed No. :  Parents occupation :  
Name  :  Income :  
Age  :  Date of admission :  
Sex :  Date of discharge :  
Address  :  Diagnosis  :  
Informant :  Medical officer  :  
      
      
1. Complaints and duration  :  
2. History of present illness :  
3. History of past illness  :  
4. Antenatal history  :  
5. Birth history  :  
6. Neonatal history  :  
7. Developmental history  :  
8. Nutritional history   :  
9. Immunization history  :  
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10. Family history :  
11. Allergy and contact history  :  
12. Socio economic status :  
GENERAL EXAMINATION 
1. Level of consciousness  :  
2. Nutritional status  :  
3. Posture / Attitude  :  
4. Dysmorphic features  :  
5. Signs and respiratory distress :  
6. Anemia :  
7. Cyanosis  :  
8. Jaundice  :  
9. Clubbing :  
10. Koilonychias :  
11. Lymphadenopathy  :  
Anthropometry    
1. Height  :  
2. Weight :  
3. Head circumstances  :  
4. Mid arm circumstance  :  
Vital sign    
1. Temperature  :  
2. Pulse rate :  
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3. Respiratory rate  :  
4. Heart rate  :  
5. Blood pressure  :  
SIDDHA ASPECTS    
Nilam   
1. Kurinnji :  
2. Mullai :  
3. Marutham :  
4. Neithal :  
5. Paalai :  
Paruvakaalam   
1. Kaar :  
2. Koothir :  
3. Munpani :  
4. Pinpani :  
5. Elavenil :  
6. Muthuvenil :  
Poripulangal   
1. Mei  :  
2. Vaai :  
3. Kan :  
4. Mooku :  
5. Sevi :  
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Kanmenthiriyam   
1. Kai  :  
2. Kaal :  
3. Vaai :  
4. Eruvai :  
5. Karuvai :  
Uyirthathukkal   
Vadham   
1. Praaanan :  
2. Abaanan :  
3. Viyaanan :  
4. Uthaanan :  
5. Samaanan :  
6. Naagan :  
7. Koorman :  
8. Kirukaran :  
9. Devathathan :  
10. Dhananjeyan :  
Pitham   
1. Analpitham :  
2. Ranjagam :  
3. Saadhagam :  
4. Praasagam :  
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5. Aalossagam :  
Kabam   
1. Avalambagam :  
2. Kilethagam :  
3. Pothagam :  
4. Tharpagam :  
5. Santhigam :  
UdalKattugal   
1. Saaram :  
2. Senneer :  
3. Oonn :  
4. Kozhuppu :  
5. Enbu :  
6. Moolai :  
7. Sukkilam / Suronitham :  
Envagaithervugal   
1. Naadi :  
2. Sparisam :  
3. Naa :  
4. Niram :  
5. Mozhi :  
6. Vizhi :  
7. Malam :  
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8. Moothiram :  
MODERN ASPECTS    
Respiratory system    
1. Inspection  :  
2. Palpation  :  
3. Percussion  :  
4. Auscultation  :  
Examination of other system     
1. Cardiovascular system :  
2. Gastrointestinal system :  
3. Central nervous system  :  
4. Excretory system  :  
5. Musculoskeletal system   
Laboratory investigation      
Blood       
1. TC :  
2. DC :  
3. ESR (1 hr) :  
4. Hb % :  
Urine       
1. Albumin  :  
2. Sugar  :  
3. Deposits  :  
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Stools    
1. Ova  :  
2. Cyst  :  
Others    
1. X ray chest  :  
2. Other investigation  :  
3. Summary of the case :  
4. Differential diagnosis  :  
5. diagnosis :  
6. Treatment  :  
7. Prognosis  :  
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